WO2017053923A1 - Viral conjunctivitis treatment using ranpirnase and/or amphinase - Google Patents
Viral conjunctivitis treatment using ranpirnase and/or amphinase Download PDFInfo
- Publication number
- WO2017053923A1 WO2017053923A1 PCT/US2016/053629 US2016053629W WO2017053923A1 WO 2017053923 A1 WO2017053923 A1 WO 2017053923A1 US 2016053629 W US2016053629 W US 2016053629W WO 2017053923 A1 WO2017053923 A1 WO 2017053923A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- seq
- amphinase
- ranpirnase
- disclosed
- individual
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
- A61K9/0051—Ocular inserts, ocular implants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
- C12Y301/27—Endoribonucleases producing 3'-phosphomonoesters (3.1.27)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
- C12Y301/27—Endoribonucleases producing 3'-phosphomonoesters (3.1.27)
- C12Y301/27005—Pancreatic ribonuclease (3.1.27.5)
Definitions
- Conjunctivitis commonly referred to as pink eye, is an inflammation of the eye causing swelling and irritation. It affects the conjunctiva, the thin transparent membrane that covers the sclera of the eyeball and lines the inner surface of the eyelid. Conjunctivitis is most often caused by a viral or by a bacterial infection, although allergies, chemical irritants, and underlying diseases can also play a role.
- Symptoms of conjunctivitis include, without limitation, redness in the sclera and/or inner eyelid, ocular itching (itchy eyes), foreign body sensation (gritty or scratchy eyes), burning eyes, blurred vision, increased sensitivity to light or photophobia, swollen inner eyelids, increased tear production, watery discharge, mucopurulent discharge that can crusts over eyelashes while sleeping. Both viral and bacterial conjunctivitis are highly contagious.
- bacterial conjunctivitis can be treated using antibiotics in the form of eye drops, pills or an ointment. Eye drops or ointments may need to be applied to the inside of the eyelid three to four times a day for five to seven days. Pills may need to be taken for several days. Treatment helps shorten the course of the infection, and associated symptoms, which usually lasts 2 to 21 days. Treatment will also decrease the amount of time an individual suffering from bacterial conjunctivitis is contagious. Unlike bacterial infection, there is currently no effective treatment for viral conjunctivitis.
- conjunctivitis is typically a self-limited disease, certain forms of conjunctivitis are serious and sight-threatening because the disease can cause cornea scarring.
- the more severe forms of conjunctivitis include bacterial conjunctivitis caused by gonorrhea and chlamydia as well as viral conjunctivitis caused by certain strains of the adeno virus.
- aspects of the present specification disclose a method of treating an individual with a viral conjunctivitis.
- the disclosed method comprises administering to an individual in need thereof a pharmaceutical composition comprising a therapeutic effective amount of one or more Ranpirnases and/or a therapeutic effective amount of one or more Amphinase.
- Such administration reduces a symptom associated with the viral conjunctivitis, thereby treating the individual.
- a pharmaceutical composition comprising one or more Ranpirnases and/or one or more Amphinase for treating of a viral conjunctivitis.
- a viral conjunctivitis disclosed herein includes an epidemic keratoconjunctivitis, a pharingoconjunctival fever, a nonspecific sporadic follicular conjunctivitis, or a chronic papillary conjunctivitis.
- a viral conjunctivitis disclosed herein may be caused by a Human adenovirus B, a Human adenovirus D, or a Human adenovirus E.
- the disclosed methods comprises administering to an individual in need thereof a pharmaceutical composition comprising a therapeutic effective amount of one or more Ranpirnases and/or a therapeutic effective amount of one or more Amphinase. Such administration reduces or suppresses a level of a virus, viral titer, viral replication, protein synthesis and/or tRNA.
- a pharmaceutical composition comprising one or more Ranpirnases and/or one or more Amphinase for reducing or suppressing a level of a virus, viral titer, viral replication, protein synthesis and/or tRNA in an individual.
- the disclosed method comprises administering to an individual in need thereof a pharmaceutical composition comprising a therapeutic effective amount of one or more Ranpirnases and/or a therapeutic effective amount of one or more Amphinase. Such administration reduces or suppresses a level of an inflammation inducing molecule. Also disclosed is a use of a pharmaceutical composition comprising one or more Ranpirnases and/or one or more Amphinase for reducing or suppressing a level of an inflammation inducing molecule.
- An inflammation inducing molecule disclosed herein includes a substance P, a calcitonin gene-related peptide, a glutamate, or a combination thereof.
- the disclosed method comprises administering to an individual in need thereof a pharmaceutical composition comprising a therapeutic effective amount of one or more Ranpirnases and/or a therapeutic effective amount of one or more Amphinase. Such administration reduces or suppresses a level of an inflammation inducing prostaglandin. Also disclosed is a use of a pharmaceutical composition comprising one or more Ranpirnases and/or one or more Amphinase for reducing or suppressing a level of an inflammation inducing prostaglandin.
- An inflammation inducing prostaglandin includes 15dPGJ2.
- a method of stimulating or enhancing a peroxisome proliferator-activated receptor (PPAR) signaling pathway activity in an individual comprises administering to an individual in need thereof a pharmaceutical composition comprising a therapeutic effective amount of one or more Ranpirnases and/or a therapeutic effective amount of one or more Amphinase. Such administration stimulates or enhances a PPAR signaling pathway activity. Also disclosed is a use of a pharmaceutical composition comprising one or more Ranpirnases and/or one or more Amphinase for stimulating or enhancing a PPAR signaling pathway activity.
- a PPAR signaling pathway activity includes a PPAR-a signaling pathway activity, a PPAR- ⁇ signaling pathway activity, and a PPAR- ⁇ (also known as PPAR- ⁇ ) signaling pathway activity [01 1]
- the disclosed method comprises administering to an individual in need thereof a pharmaceutical composition comprising a therapeutic effective amount of one or more Ranpirnases and/or a therapeutic effective amount of one or more Amphinase.
- Such administration induces apoptosis of Macrophage M1 cells, promotes differentiation of Macrophage M2 cells or both, thereby promoting the resolving phenotypic change of M1 to M2.
- a pharmaceutical composition comprising one or more Ranpirnases and/or one or more Amphinase for promoting the resolving phenotypic change of M1 to M2.
- a method of modulating a level of a Th1 cytokine and/or a level of a Th2 cytokine in an individual comprises administering to an individual in need thereof a pharmaceutical composition comprising a therapeutic effective amount of one or more Ranpirnases and/or a therapeutic effective amount of one or more Amphinase.
- Such administration reduces the levels of Interferon-gamma (IFNy), Tumor necrosis factor-alpha (TNF-a), lnterleukin-1 b (IL-1 b), lnterleukin-12 (IL- 12), or a combination thereof released from a Th1 cell, increases the level of IL-10 released from a Th2 cell, or both, thereby modulating a level of a Th1 cytokine and/or Th2 cytokine.
- a pharmaceutical composition comprising one or more Ranpirnases and/or one or more Amphinase for modulating a level of a Th1 cytokine and/or a level of a Th2 cytokine.
- a method of reducing or suppressing a NFKB signaling pathway activity in an individual comprises administering to an individual in need thereof a pharmaceutical composition comprising a therapeutic effective amount of one or more Ranpirnases and/or a therapeutic effective amount of one or more Amphinase. Such administration reduces or suppresses the NFKB signaling pathway activity. Also disclosed is a use of a pharmaceutical composition comprising one or more Ranpirnases and/or one or more Amphinase for reducing or suppressing a NFKB signaling pathway activity.
- Viruses constitute important pathogens that can infect animals, including humans and plants. Despite their great diversity, all viruses are obligate intracellular parasites, meaning that each is dependent on the host cell and its cellular processes to complete their replicative cycle. As a first step to completing their replicative cycle, a virus needs to invade a host cell. This is achieved by proteins on the surface of the virus interacting with proteins on the surface of the host cell, enabling the virus to become attached to or adsorbed into the cell membrane. Such association triggers a breach in the cell membrane allowing the virus or its genetic contents to be released into the cytoplasm of the host cell.
- a virus co-opts the replication mechanisms of the infected host cell in order making copies of its genome and packaging these copies into newly synthesized viral particles.
- virus progeny are released from the infected host cell by budding or apoptosis in order to find new host cells to infect.
- both enveloped and non-enveloped viruses induce several global metabolic changes on infected cells including the rearrangement of phospholipids and sialic acid-rich gangliosides in the plasma membrane of the host cell.
- the increased presence of sialic acid-rich gangliosides and anionic phospholipids leads to an increased electro-negativity of the plasma membrane.
- the lipid bilayer of the cell membrane is organized in such a way that anionic phospholipids are located on the intracellular side of the membrane. This anionic phospholipid asymmetry is actively maintained by ATP-dependent transport processes that translocate these phospholipids extracellular side to the intracellular side of the plasma membrane.
- a Ranpirnase and/or an Amphinase disclosed herein are strongly cationic molecules, these proteins would have greater electrostatic affinity to the anionic, electro-negativity charged surface of virus-infected cells and consequently would be more avidly internalized by cells infected by a virus.
- Cells uninfected with virus would be unable to transport a Ranpirnase and/or an Amphinase disclosed herein into its cytoplasm because its plasma membranes lack anionic, electro-negativity charged surfaces.
- a Ranpirnase and/or an Amphinase disclosed herein interact in a highly preferential way with cells infected with a virus. This high selectivity for virally-infected cells has enabled the investigation of a Ranpirnase and/or an Amphinase disclosed herein for developing treatment for virally-caused diseases and disorders.
- Ranpirnases and Amphinases compositions comprising these enzymes and method and uses to treat a viral conjunctivitis, an epidemic keratoconjunctivitis, and/or a pharingoconjunctival fever, reduce or suppress a level of virus or viral titer, reduce or suppress viral replication, reduce or suppress protein synthesis, reduce or suppress a level of a tRNA, reduce or suppress a level of an inflammation inducing molecule and/or an inflammation inducing prostaglandin, stimulate or enhance a peroxisome proliferator-activated receptor (PPAR) pathway signal, promote the resolving phenotypic change of M1 to M2, modulate Th1 and Th2 cytokines, and/or reduce or suppress a NFKB pathway signal using such Ranpirnases, Amphinases or compositions comprising such Ranpirnases and/or Amphinases.
- a Ranpirnase and Amphinase disclosed herein are
- Viral conjunctivitis has two main attributes that need mitigation, the presence and replication of virus and the host immune response that leads to clinical symptoms. For a successful therapy, addressing only one of these two facets is not enough.
- a Ranpirnase or Amphinase disclosed herein appear to have both antiviral and immunomodulatory mechanisms of action.
- Ranpirnase is an amphibian ribonuclease originally isolated from oocytes and/or early embryos of the Rana pipiens (the Northern Leopard frog). Originally called P-30 Protein or P-30, Ranpirnase is a member of the pancreatic ribonuclease (RNase A) protein superfamily. Initially expressed as a precursor polypeptide, Ranpirnase is processed to remove both the precursor peptide portion and the start methionine to produce a basic, lysine- rich, enzyme having a molecular weight of about 12kD.
- RNase A pancreatic ribonuclease
- the N-terminal pyroglutamyl residue is an integral part of Ranpirnase active site and significantly contributing to the catalytic and biological activities of Ranpirnase as well as to its unusually high conformational stability.
- Another structural feature of Ranpirnase is the C-terminal disulfide bond (87-104) that stabilizes the protein compact structure. This, in turn, makes Ranpirnase highly resistant to endogenous proteases.
- Another feature of Ranpirnase that makes it resistant to endogenous proteases is the low intracellular binding affinity observed for specific RNase inhibitors, allowing Ranpirnase to remain active inside the cell while the majority of mammalian RNases are inhibited.
- Ranpirnase primarily targets rapidly replicating and/or growing cells by binding to cell surface receptors and internalizing into the cytoplasm via AP-2/clathrin-mediated endocytosis. The enzyme is then shuttled to the endoplasmic reticulum where it degrades RNA substrates with a sequence preference for uracil and guanine nucleotides. For example, cleavage site mapping using natural Transfer RNA (tRNA) substrates in vitro revealed predominant cleavage sites at UG and GG residues as well as cleavage at CG sites.
- tRNA Transfer RNA
- Transfer RNA appears to be preferentially targeted as a substrate by Ranpirnase, which leaves messenger RNA (mRNA) and ribosomal RNA (rRNA) undamaged.
- mRNA messenger RNA
- rRNA ribosomal RNA
- the degradation of tRNA by Ranpirnase results in the inhibition of protein synthesis.
- NFKB nuclear factor kappa-light-chain-enhancer of activated B cells
- tumor necrosis factor alpha TNFa
- Interleukin 1 -b IL-1 b
- TNFa tumor necrosis factor alpha
- IL-1 b Interleukin 1 -b
- Proinflammatory cytokines attract inflammatory cells to sites of inflammation, enzymes which generate mediators of inflammation, immune receptors, and adhesion molecules that play an important role in the initial recruitment of neutrophils and macrophages to sites of inflammation.
- Ranpirnase has been shown to: 1) inhibit replication of HIV-1 (as an example) by up to 99.9% in the p24 antigen assay at final concentrations that are not cytotoxic; 2) inhibit syncytia formation which often occurs during active viral infections; 3) inhibit early transactivation of viral promoter sequences by tatlll protein; and 4) degrade intracellular ⁇ viral RNA, as well as various species of cellular tRNA but not cellular mRNA or rRNA.
- a Ranpirnase disclosed herein comprises SEQ ID NO: 1 , SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 , SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 21 , SEQ ID NO: 22, SEQ ID NO: 23, SEQ ID NO: 24, SEQ ID NO: 25, or SEQ ID NO: 26.
- a Ranpirnase disclosed herein has an amino acid identity of, e.g., at least 75%, at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91 %, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99%, to SEQ ID NO: 1 , SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 1 1 , SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 21 , SEQ ID NO:
- a Ranpirnase disclosed herein has an amino acid identity in the range of, e.g., about 75% to about 100%, about 80% to about 100%, about 85% to about 100%, about 90% to about 100%, about 95% to about 100%, about 75% to about 99%, about 80% to about 99%, about 85% to about 99%, about 90% to about 99%, about 95% to about 99%, about 75% to about 97%, about 80% to about 97%, about 85% to about 97%, about 90% to about 97%, or about 95% to about 97%, to SEQ ID NO: 1 , SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 1 1 , SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO:
- a Ranpirnase disclosed herein has, e.g., at least 1 , 2, 3, 4, 5,
- SEQ ID NO: 1 SEQ ID NO: 2
- SEQ ID NO: 3 SEQ ID NO: 4
- SEQ ID NO: 5 SEQ ID NO: 6
- SEQ ID NO: 7 SEQ ID NO: 8 SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 1 1 , SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 21 , SEQ ID NO: 22, SEQ ID NO: 23, SEQ ID NO: 24, SEQ ID NO: 25, or SEQ ID NO: 26; or at most 1 , 2, 3, 4, 5, 6, 7, 8, 9, 10, 1 1 , 12, 13, 14, or 15 contiguous amino acid deletions, additions, and/or substitutions relative to SEQ ID NO: 1 , SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 , SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID
- a Ranpirnase disclosed herein has, e.g., at least 1 , 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 , 12, 13, 14, or 15 non-contiguous amino acid deletions, additions, and/or substitutions relative to SEQ ID NO: 1 , SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 1 1 , SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 21 , SEQ ID NO: 22, SEQ ID NO: 23, SEQ ID NO: 24, SEQ ID NO: 25, or SEQ ID NO: 26; or at most 1 , 2, 3, 4, 5, 6, 7, 8, 9, 10, 1 1 , 12, 13, 14, or 15 non-contig
- a Ranpirnase disclosed herein can have the N-terminus blocked with pyroglutamic acid ( ⁇ Glu).
- the pyroglutamic acid N-terminus block is produced by autocyclization of glutamine (Gin).
- a Ranpirnase disclosed herein can also have the N-terminus blocked with pyrrolidone carboxylic acid.
- a Ranpirnase comprising SEQ ID NO: 1 , SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 1 1 , SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 21 , SEQ ID NO: 22, SEQ ID NO: 23, SEQ ID NO: 24, SEQ ID NO: 25, or SEQ ID NO: 26 has its N-terminus blocked with pyroglutamic acid or pyrrolidone carboxylic acid.
- aspects of the present disclosure comprise, in part, an Amphinase.
- Amphinase Another member of the pancreatic RNase A protein superfamily, Amphinase was also isolated from amphibians and is a more basic variant of Ranpirnase. Initially expressed as a precursor polypeptide, Amphinase is processed to remove both the precursor peptide portion and the start methionine to produce an active enzyme having a molecular weight of about 13kD. Like Ranpirnase, Amphinase primarily targets rapidly replicating and/or growing cells by degrading RNA and at a minimum inhibit protein synthesis.
- an Amphinase disclosed herein comprises SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 29, SEQ ID NO: 30, SEQ ID NO: 31 , SEQ ID NO: 32, SEQ ID NO: 33, SEQ ID NO: 34, SEQ ID NO: 35, SEQ ID NO: 36, SEQ ID NO: 37, SEQ ID NO: 38, or SEQ ID NO: 39.
- an Amphinase disclosed herein has an amino acid identity of, e.g., at least 75%, at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91 %, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99%, to SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 29, SEQ ID NO: 30, SEQ ID NO: 31 , SEQ ID NO: 32, SEQ ID NO: 33, SEQ ID NO: 34, SEQ ID NO: 35, SEQ ID NO: 36, SEQ ID NO: 37, SEQ ID NO: 38, or SEQ ID NO: 39.
- an Amphinase disclosed herein has an amino acid identity in the range of, e.g., about 75% to about 100%, about 80% to about 100%, about 85% to about 100%, about 90% to about 100%, about 95% to about 100%, about 75% to about 99%, about 80% to about 99%, about 85% to about 99%, about 90% to about 99%, about 95% to about 99%, about 75% to about 97%, about 80% to about 97%, about 85% to about 97%, about 90% to about 97%, or about 95% to about 97%, to SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 29, SEQ ID NO: 30, SEQ ID NO: 31 , SEQ ID NO: 32, SEQ ID NO: 33, SEQ ID NO: 34, SEQ ID NO: 35, SEQ ID NO: 36, SEQ ID NO: 37, SEQ ID NO: 38, or SEQ ID NO: 39.
- an Amphinase disclosed herein has, e.g., at least 1 , 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 , 12, 13, 14, or 15 contiguous amino acid deletions, additions, and/or substitutions relative to SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 29, SEQ ID NO: 30, SEQ ID NO: 31 , SEQ ID NO:
- SEQ ID NO: 33 SEQ ID NO: 34, SEQ ID NO: 35, SEQ ID NO: 36, SEQ ID NO: 37, SEQ ID NO: 38, or SEQ ID NO: 39; or at most 1 , 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 , 12, 13, 14, or 15 contiguous amino acid deletions, additions, and/or substitutions relative to SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 29, SEQ ID NO: 30, SEQ ID NO: 31 , SEQ ID NO: 32, SEQ ID NO: 33, SEQ ID NO: 34, SEQ ID NO: 35, SEQ ID NO: 36, SEQ ID NO: 37, SEQ ID NO: 38, or SEQ ID NO: 39.
- an Amphinase disclosed herein has, e.g., at least 1 , 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 , 12, 13, 14, or 15 non-contiguous amino acid deletions, additions, and/or substitutions relative to SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 29, SEQ ID NO: 30, SEQ ID NO: 31 , SEQ ID NO: 32, SEQ ID NO: 33, SEQ ID NO: 34, SEQ ID NO: 35, SEQ ID NO: 36, SEQ ID NO: 37, SEQ ID NO: 38, or SEQ ID NO: 39; or at most 1 , 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 , 12, 13, 14, or 15 non-contiguous amino acid deletions, additions, and/or substitutions relative to SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 29, SEQ ID NO: 30, SEQ ID NO: 31 , SEQ ID NO: 32, SEQ ID NO:
- SEQ ID NO: 34 SEQ ID NO: 35, SEQ ID NO: 36, SEQ ID NO: 37, SEQ ID NO: 38, or SEQ ID NO: 39.
- a Ranpirnase and/or Amphinase disclosed herein can be recombinantly engineered to add functional domains without inhibiting the endogenous activity of a Ranpirnase and/or Amphinase disclosed herein.
- an Eosinophilic Cationic Protein fragment can be added to a Ranpirnase and/or Amphinase disclosed herein in order to provide or significantly improve bactericidal properties.
- Such constructs are described in Torrent, et al., "Bactericidal Activity Engineered on Human Pancreatic Ribonuclease and Onconase", Mol. Pharm. 6(2): 531 -542 (2009), which is incorporated by reference in its entirety. This could be of significant value if a single therapeutic could treat both bacterial and viral conjunctivitis, while still addressing the common underlying immune response to such stress.
- the present specification describes various polypeptide variants where one amino acid is substituted for another, such as, e.g., a Ranpirnase disclosed herein or an Amphinase disclosed herein.
- a substitution can be assessed by a variety of factors, such as, e.g., the physic properties of the amino acid being substituted (Table 1) or how the original amino acid would tolerate a substitution (Table 2).
- Table 1 the physic properties of the amino acid being substituted
- Table 2 how the original amino acid would tolerate a substitution
- the selections of which amino acid can be substituted for another amino acid in a polypeptide are known to a person of ordinary skill in the art.
- a hydrophobic amino acid at one particular position in a Ranpirnase and/or Amphinase disclosed herein can be substituted with another hydrophobic amino acid.
- hydrophobic amino acids include, e.g., C, F, I, L, M, V and W.
- an aliphatic amino acid at one particular position in a Ranpirnase and/or Amphinase disclosed herein can be substituted with another aliphatic amino acid.
- aliphatic amino acids include, e.g., A, I, L, P, and V.
- an aromatic amino acid at one particular position in a Ranpirnase and/or Amphinase disclosed herein can be substituted with another aromatic amino acid.
- aromatic amino acids include, e.g. , F, H, W and Y.
- a stacking amino acid at one particular position in a Ranpirnase and/or Amphinase disclosed herein can be substituted with another stacking amino acid. Examples of stacking amino acids include, e.g., F, H, W and Y.
- a polar amino acid at one particular position in a Ranpirnase and/or Amphinase disclosed herein can be substituted with another polar amino acid.
- polar amino acids examples include, e.g., D, E, K, N, Q, and R.
- a less polar or indifferent amino acid at one particular position in a Ranpirnase and/or Amphinase disclosed herein can be substituted with another less polar or indifferent amino acid.
- examples of less polar or indifferent amino acids include, e.g., A, H, G, P, S, T, and Y.
- a positive charged amino acid at one particular position in a Ranpirnase and/or Amphinase disclosed herein can be substituted with another positive charged amino acid.
- positive charged amino acids examples include, e.g., K, R, and H.
- a negative charged amino acid at one particular position in a Ranpirnase and/or Amphinase disclosed herein can be substituted with another negative charged amino acid.
- negative charged amino acids include, e.g., D and E.
- a small amino acid at one particular position in a Ranpirnase and/or Amphinase disclosed herein can be substituted with another small amino acid.
- small amino acids include, e.g., A, D, G, N, P, S, and T.
- a C-beta branching amino acid at one particular position in a Ranpirnase and/or Amphinase disclosed herein can be substituted with another C- beta branching amino acid.
- C-beta branching amino acids include, e.g., I, T and V.
- a Ranpirnase and/or Amphinase disclosed herein has an anti-viral activity capable of reducing or suppressing a level of virus or viral titer.
- a Ranpirnase and/or Amphinase disclosed herein has an anti-viral activity capable of reducing or suppressing a level of virus or viral titer by, e.g., at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90% or at least 95%.
- a Ranpirnase and/or Amphinase disclosed herein has an anti-viral activity capable of reducing or suppressing a level of virus or viral titer in a range from, e.g., about 10% to about 100%, about 20% to about 100%, about 30% to about 100%, about 40% to about 100%, about 50% to about 100%, about 60% to about 100%, about 70% to about 100%, about 80% to about 100%, about 10% to about 90%, about 20% to about 90%, about 30% to about 90%, about 40% to about 90%, about 50% to about 90%, about 60% to about 90%, about 70% to about 90%, about 10% to about 80%, about 20% to about 80%, about 30% to about 80%, about 40% to about 80%, about 50% to about 80%, or about 60% to about 80%, about 10% to about 70%, about 20% to about 70%, about 30% to about 70%, about 40% to about 70%, or about 50% to about 70%.
- a Ranpirnase and/or Amphinase disclosed herein has an anti-viral activity capable of reducing or suppressing viral replication.
- a Ranpirnase and/or Amphinase disclosed herein has an anti-viral activity capable of reducing or suppressing viral replication by, e.g., at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90% or at least 95%.
- a Ranpirnase and/or Amphinase disclosed herein has an anti-viral activity capable of reducing or suppressing viral replication in a range from, e.g. , about 10% to about 100%, about 20% to about 100%, about 30% to about 100%, about 40% to about 100%, about 50% to about 100%, about 60% to about 100%, about 70% to about 100%, about 80% to about 100%, about 10% to about 90%, about 20% to about 90%, about 30% to about 90%, about 40% to about 90%, about 50% to about 90%, about 60% to about 90%, about 70% to about 90%, about 10% to about 80%, about 20% to about 80%, about 30% to about 80%, about 40% to about 80%, about 50% to about 80%, or about 60% to about 80%, about 10% to about 70%, about 20% to about 70%, about 30% to about 70%, about 40% to about 70%, or about 50% to about 70%.
- a Ranpirnase and/or Amphinase disclosed herein has an anti-viral activity capable of reducing or suppressing protein synthesis in one or more cells.
- a Ranpirnase and/or Amphinase disclosed herein has an anti-viral activity capable of reducing or suppressing protein synthesis in one or more cells by, e.g., at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90% or at least 95%.
- a Ranpirnase and/or Amphinase disclosed herein has an anti-viral activity capable of reducing or suppressing protein synthesis in one or more cells in a range from, e.g., about 10% to about 100%, about 20% to about 100%, about 30% to about 100%, about 40% to about 100%, about 50% to about 100%, about 60% to about 100%, about 70% to about 100%, about 80% to about 100%, about 10% to about 90%, about 20% to about 90%, about 30% to about 90%, about 40% to about 90%, about 50% to about 90%, about 60% to about 90%, about 70% to about 90%, about 10% to about 80%, about 20% to about 80%, about 30% to about 80%, about 40% to about 80%, about 50% to about 80%, or about 60% to about 80%, about 10% to about 70%, about 20% to about 70%, about 30% to about 70%, about 40% to about 70%, or about 50% to about 70%.
- a Ranpirnase and/or Amphinase disclosed herein has an anti-viral activity capable of reducing or suppressing a level of tRNA in one or more cells.
- a Ranpirnase and/or Amphinase disclosed herein has an anti-viral activity capable reducing or suppressing a level of tRNA in one or more cells by, e.g., at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90% or at least 95%.
- a Ranpirnase and/or Amphinase disclosed herein has an anti-viral activity capable reducing or suppressing a level of tRNA in one or more cells in a range from, e.g., about 10% to about 100%, about 20% to about 100%, about 30% to about 100%, about 40% to about 100%, about 50% to about 100%, about 60% to about 100%, about 70% to about 100%, about 80% to about 100%, about 10% to about 90%, about 20% to about 90%, about 30% to about 90%, about 40% to about 90%, about 50% to about 90%, about 60% to about 90%, about 70% to about 90%, about 10% to about 80%, about 20% to about 80%, about 30% to about 80%, about 40% to about 80%, about 50% to about 80%, or about 60% to about 80%, about 10% to about 70%, about 20% to about 70%, about 30% to about 70%, about 40% to about 70%, or about 50% to about 70%.
- a Ranpirnase and/or Amphinase disclosed herein has an anti-inflammatory activity capable of reducing the levels of an inflammation inducing molecule.
- a Ranpirnase and/or Amphinase disclosed herein has an anti-inflammatory activity capable of reducing the levels of substance P (SP), calcitonin gene-related peptide (CGRP), glutamate, or a combination thereof.
- SP substance P
- CGRP calcitonin gene-related peptide
- glutamate glutamate
- a Ranpirnase and/or Amphinase disclosed herein has an anti-inflammatory activity capable of reducing the levels of SP, CGRP, glutamate, or a combination thereof released from a sensory neuron by, e.g., at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90% or at least 95%.
- a Ranpirnase and/or Amphinase disclosed herein has an anti-inflammatory activity capable of reducing the levels of SP, CGRP, glutamate, or a combination thereof released from a sensory neuron in a range from, e.g., about 10% to about 100%, about 20% to about 100%, about 30% to about 100%, about 40% to about 100%, about 50% to about 100%, about 60% to about 100%, about 70% to about 100%, about 80% to about 100%, about 10% to about 90%, about 20% to about 90%, about 30% to about 90%, about 40% to about 90%, about 50% to about 90%, about 60% to about 90%, about 70% to about 90%, about 10% to about 80%, about 20% to about 80%, about 30% to about 80%, about 40% to about 80%, about 50% to about 80%, or about 60% to about 80%, about 10% to about 70%, about 20% to about 70%, about 30% to about 70%, about 40% to about 70%, or about 50% to about 70%.
- Prostaglandins mediate a local inflammatory response and are involved in all inflammatory functions through action on prostaglandin receptors and mediate inflammatory signaling including chemotaxis (macrophages, neutrophils and eosinophils), vasodilation and algesia.
- chemotaxis macrophages
- neutrophils neutrophils
- eosinophils vasodilation
- algesia the PG- mediated inflammatory response is self-limiting (resolving).
- the principle resolution factor is a prostaglandin called 15dPGJ2, which is an endogenous agonist of peroxisome proliferator-activator receptor gamma (PPAR- ⁇ ) signaling.
- PPARy signaling pathway 1 induces apoptosis of Macrophage M1 cells, thereby reducing the levels of Th1 pro-inflammatory cytokines and 2) promotes differentiation of monocytes into Macrophage M2 cells.
- Macrophage M2 cells produce and release Th2 a nti- inflammatory cytokines.
- a Ranpirnase and/or Amphinase disclosed herein has an anti-inflammatory activity capable of reducing the levels of an inflammation inducing prostaglandin.
- a Ranpirnase and/or Amphinase disclosed herein has an anti-inflammatory activity capable of reducing the levels of an inflammation inducing prostaglandin released from a sensory neuron by, e.g., at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90% or at least 95%.
- a Ranpirnase and/or Amphinase disclosed herein has an anti-inflammatory activity capable of reducing the levels of an inflammation inducing prostaglandin released from a sensory neuron in a range from, e.g., about 10% to about 100%, about 20% to about 100%, about 30% to about 100%, about 40% to about 100%, about 50% to about 100%, about 60% to about 100%, about 70% to about 100%, about 80% to about 100%, about 10% to about 90%, about 20% to about 90%, about 30% to about 90%, about 40% to about 90%, about 50% to about 90%, about 60% to about 90%, about 70% to about 90%, about 10% to about 80%, about 20% to about 80%, about 30% to about 80%, about 40% to about 80%, about 50% to about 80%, or about 60% to about 80%, about 10% to about 70%, about 20% to about 70%, about 30% to about 70%, about 40% to about 70%, or about 50% to about 70%.
- a Ranpirnase and/or Amphinase disclosed herein has an anti-inflammatory activity substantially similar to 15dPGJ2.
- a Ranpirnase and/or Amphinase disclosed herein an anti-inflammatory activity that is, e.g., at least 5%, at least 15%, at least 25%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90% or at least 95% of the activity observed for 15dPGJ2.
- a Ranpirnase and/or Amphinase disclosed herein an anti-inflammatory activity that is in a range from, e.g., about 5% to about 100%, about 50% to about 100%, about 60% to about 100%, about 70% to about 100%, about 80% to about 100%, about 25% to about 90%, about 50% to about 90%, about 60% to about 90%, about 70% to about 90%, about 80% to about 90%, about 25% to about 80%, about 50% to about 80%, about 60% to about 80%, about 70% to about 80%, about 25% to about 70%, about 50% to about 70%, about 25% to about 60%, about 50% to about 60%, or about 25% to about 50% of the activity observed for 15dPGJ2.
- the peroxisome proliferator-activated receptors are a group of nuclear receptor proteins that function as transcription factors regulating the expression of genes. All PPARs are known to heterodimerize with the retinoid X receptor (RXR) and bind to specific regions on the DNA of target genes called peroxisome proliferator hormone response elements (PPREs). PPARs play essential roles in the regulation of cellular differentiation, development, and metabolism (carbohydrate, lipid, protein), and tumorigenesis of higher organisms. The family comprises three members, PPAR-a, PPAR- ⁇ , and PPAR- ⁇ (also known as PPAR- ⁇ ).
- PPAR-a is expressed in liver, kidney, heart, muscle, adipose tissue, as well as othertissues.
- PPAR- ⁇ is expressed in many tissues but markedly in brain, adipose tissue, and skin.
- PPAR- Y comprises three alternatively-spliced forms, each with a different expression pattern.
- PPAR- ⁇ is expressed in virtually all tissues, including heart, muscle, colon, kidney, pancreas, and spleen.
- PPAR-Y2 is expressed mainly in adipose tissue.
- PPAR-Y3 is expressed in macrophages, large intestine, and white adipose tissue. Endogenous ligands for the PPARs include free fatty acids and eicosanoids.
- PPAR- ⁇ is activated by PGJ2 (a prostaglandin), whereas PPAR-a is activated by leukotriene B4.
- a Ranpirnase and/or Amphinase disclosed herein has an anti-inflammatory activity capable of stimulating or enhancing activity from all PPAR signaling pathways. In other embodiments, a Ranpirnase and/or Amphinase disclosed herein has an anti-inflammatory activity capable of stimulating or enhancing activity of one or two of the PPAR signaling pathways.
- a Ranpirnase and/or Amphinase disclosed herein has an anti-inflammatory activity capable of stimulating or enhancing a PPAR-a signaling pathway activity.
- a Ranpirnase and/or Amphinase disclosed herein stimulates or enhances a PPAR-a signaling pathway activity by, e.g., at least 5%, at least 15%, at least 25%, at least 50%, at least 60%, at least 70%, at least 80%, or at least 90%.
- a Ranpirnase and/or Amphinase disclosed herein stimulates or enhances a PPAR-a signaling pathway activity in a range from, e.g., about 5% to about 100%, about 50% to about 100%, about 60% to about 100%, about 70% to about 100%, about 80% to about 100%, about 25% to about 90%, about 50% to about 90%, about 60% to about 90%, about 70% to about 90%, about 80% to about 90%, about 25% to about 80%, about 50% to about 80%, about 60% to about 80%, about 70% to about 80%, about 25% to about 70%, about 50% to about 70%, about 25% to about 60%, about 50% to about 60%, or about 25% to about 50%.
- a Ranpirnase and/or Amphinase disclosed herein has an anti-inflammatory activity capable of stimulating or enhancing a PPAR- ⁇ signaling pathway activity.
- a Ranpirnase and/or Amphinase disclosed herein stimulates or enhances a PPAR- ⁇ signaling pathway activity by, e.g., at least 5%, at least 15%, at least 25%, at least 50%, at least 60%, at least 70%, at least 80%, or at least 90%.
- a Ranpirnase and/or Amphinase disclosed herein stimulates or enhances a PPAR- ⁇ signaling pathway activity in a range from, e.g., about 5% to about 100%, about 50% to about 100%, about 60% to about 100%, about 70% to about 100%, about 80% to about 100%, about 25% to about 90%, about 50% to about 90%, about 60% to about 90%, about 70% to about 90%, about 80% to about 90%, about 25% to about 80%, about 50% to about 80%, about 60% to about 80%, about 70% to about 80%, about 25% to about 70%, about 50% to about 70%, about 25% to about 60%, about 50% to about 60%, or about 25% to about 50%.
- a Ranpirnase and/or Amphinase disclosed herein has an anti-inflammatory activity capable of stimulating or enhancing a PPARy signaling pathway activity.
- a Ranpirnase and/or Amphinase disclosed herein stimulates or enhances a PPARy signaling pathway activity by, e.g., at least 5%, at least 15%, at least 25%, at least 50%, at least 60%, at least 70%, at least 80%, or at least 90%.
- a Ranpirnase and/or Amphinase disclosed herein stimulates or enhances a PPARy signaling pathway activity in a range from, e.g., about 5% to about 100%, about 50% to about 100%, about 60% to about 100%, about 70% to about 100%, about 80% to about 100%, about 25% to about 90%, about 50% to about 90%, about 60% to about 90%, about 70% to about 90%, about 80% to about 90%, about 25% to about 80%, about 50% to about 80%, about 60% to about 80%, about 70% to about 80%, about 25% to about 70%, about 50% to about 70%, about 25% to about 60%, about 50% to about 60%, or about 25% to about 50%.
- Macrophages are activated and polarized into distinct phenotypes expressing unique cell surface molecules and secreting discrete sets of cytokines and chemokines.
- the classical M1 phenotype supports pro-inflammatory Th1 responses driven by cytokines such as, e.g., lnterleukin-6 (IL-6), IL-12 and IL-23, while the alternate M2 phenotype is generally supportive of anti-inflammatory processes driven by IL-10.
- M2 cells can be further classified into subsets, M2a, M2b, and M2c, based on the type of stimulation and the subsequent expression of surface molecules and cytokines.
- a Ranpirnase and/or Amphinase disclosed herein has an antiinflammatory activity capable of promoting the resolving phenotypic change of M1 to M2.
- a Ranpirnase and/or Amphinase disclosed herein has an anti-inflammatory activity capable of inducing apoptosis of Macrophage M1 cells.
- a Ranpirnase and/or Amphinase disclosed herein has an anti-inflammatory activity capable of promoting differentiation of Macrophage M2 cells.
- a Ranpirnase and/or Amphinase disclosed herein has an anti-inflammatory activity capable of inducing apoptosis of Macrophage M1 cells and promoting differentiation of Macrophage M2 cells.
- a Ranpirnase and/or Amphinase disclosed herein has an antiinflammatory activity capable of modulating the levels of a Th1 cytokine and/or Th2 cytokine.
- a Ranpirnase and/or Amphinase disclosed herein has an anti-inflammatory activity capable of reducing a level of Interferon-gamma (IFNy), Tumor necrosis factor-alpha (TNF-a), Interleukin- 1 b (IL-1 b), lnterleukin-12 (IL-12), or a combination thereof released from a Th1 cell.
- IFNy Interferon-gamma
- TNF-a Tumor necrosis factor-alpha
- IL-1 b Interleukin- 1 b
- IL-12 lnterleukin-12
- a Ranpirnase and/or Amphinase disclosed herein has an anti-inflammatory activity capable of reducing a level of IFNy, TNF-a, IL-1 b, IL-12, or a combination thereof released from a Th1 cell by, e.g., at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, or at least 90%.
- a Ranpirnase and/or Amphinase disclosed herein has an anti-inflammatory activity capable of reducing a level of IFNy, TNF-a, IL-1 b, IL-12, or a combination thereof released from a Th1 cell in a range from, e.g., about 5% to about 100%, about 10% to about 100%, about 20% to about 100%, about 30% to about 100%, about 40% to about 100%, about 50% to about 100%, about 60% to about 100%, about 70% to about 100%, about 80% to about 100%, about 10% to about 90%, about 20% to about 90%, about 30% to about 90%, about 40% to about 90%, about 50% to about 90%, about 60% to about 90%, about 70% to about 90%, about 10% to about 80%, about 20% to about 80%, about 30% to about 80%, about 40% to about 80%, about 50% to about 80%, or about 60% to about 80%, about 10% to about 70%, about 20% to about 70%, about 30% to about 70%, about 40% to about 70%, or about 50% to about 70%, or about 50% to about 70%
- a Ranpirnase and/or Amphinase disclosed herein has an anti-inflammatory activity capable of increasing a level of IL-10 released from a Th2 cell.
- a Ranpirnase and/or Amphinase disclosed herein has an anti-inflammatory activity capable of increasing a level of IL-10 released from a Th2 cell by, e.g., at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90% or at least 95%.
- a Ranpirnase and/or Amphinase disclosed herein has an anti-inflammatory activity capable of increasing a level of IL-10 released from a Th2 cell in a range from, e.g., about 5% to about 100%, about 10% to about 100%, about 20% to about 100%, about 30% to about 100%, about 40% to about 100%, about 50% to about 100%, about 60% to about 100%, about 70% to about 100%, about 80% to about 100%, about 10% to about 90%, about 20% to about 90%, about 30% to about 90%, about 40% to about 90%, about 50% to about 90%, about 60% to about 90%, about 70% to about 90%, about 10% to about 80%, about 20% to about 80%, about 30% to about 80%, about 40% to about 80%, about 50% to about 80%, or about 60% to about 80%, about 10% to about 70%, about 20% to about 70%, about 30% to about 70%, about 40% to about 70%, or about 50% to about 70%.
- a Ranpirnase and/or Amphinase disclosed herein has an anti-inflammatory activity capable of reducing a level of IFNy, TNF-a, IL-1 b, IL-12, or a combination thereof released from a Th1 cell and increasing a level of IL-10 released from a Th2 cell.
- a Ranpirnase and/or Amphinase disclosed herein has an anti-inflammatory activity capable of reducing a level of IFNy, TNF-a, IL-1 b, IL-12, or a combination thereof released from a Th1 cell by, e.g., at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90% or at least 95%, and capable of increasing a level of IL-10 released from a Th2 cell by, e.g., at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%
- a Ranpirnase and/or Amphinase disclosed herein has an anti-inflammatory activity capable of reducing a level of IFNy, TNF-a, IL-1 b, IL-12, or a combination thereof released from a Th1 cell in a range from, e.g., about 5% to about 100%, about 10% to about 100%, about 20% to about 100%, about 30% to about 100%, about 40% to about 100%, about 50% to about 100%, about 60% to about 100%, about 70% to about 100%, about 80% to about 100%, about 10% to about 90%, about 20% to about 90%, about 30% to about 90%, about 40% to about 90%, about 50% to about 90%, about 60% to about 90%, about 70% to about 90%, about 10% to about 80%, about 20% to about 80%, about 30% to about 80%, about 40% to about 80%, about 50% to about 80%, or about 60% to about 80%, about 10% to about 70%, about 20% to about 70%, about 30% to about 70%, about 40% to about 70%, or about 50% to about 70%, or about 50% to about 70%
- a Ranpirnase and/or Amphinase disclosed herein has an anti-inflammatory activity capable of reducing of suppressing a NFKB signaling pathway activity.
- a Ranpirnase and/or Amphinase disclosed herein has an anti-inflammatory activity capable of reducing of suppressing a NFKB signaling pathway activity by, e.g., at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, or at least 90%.
- a Ranpirnase and/or Amphinase disclosed herein has an anti-inflammatory activity capable of reducing of suppressing a NFKB signaling pathway activity in a range from, e.g., about 5% to about 100%, about 10% to about 100%, about 20% to about 100%, about 30% to about 100%, about 40% to about 100%, about 50% to about 100%, about 60% to about 100%, about 70% to about 100%, about 80% to about 100%, about 10% to about 90%, about 20% to about 90%, about 30% to about 90%, about 40% to about 90%, about 50% to about 90%, about 60% to about 90%, about 70% to about 90%, about 10% to about 80%, about 20% to about 80%, about 30% to about 80%, about 40% to about 80%, about 50% to about 80%, or about 60% to about 80%, about 10% to about 70%, about 20% to about 70%, about 30% to about 70%, about 40% to about 70%, or about 50% to about 70%.
- compositions disclosed herein are generally administered as a pharmaceutical acceptable composition.
- pharmaceutical acceptable refers any molecular entity or composition that does not produce an adverse, allergic or other untoward or unwanted reaction when administered to an individual.
- pharmaceutically acceptable composition is synonymous with “pharmaceutical composition” and means a therapeutically effective concentration of an active ingredient, such as, e.g., any one of the Ranpirnase and/or Amphinase disclosed herein.
- a pharmaceutical composition disclosed herein is useful for medical and veterinary applications.
- a pharmaceutical composition may be administered to an individual alone, or in combination with other supplementary active ingredients, agents, drugs or hormones.
- a pharmaceutical composition disclosed herein comprises one or more Ranpirnase disclosed herein and/or one or more Amphinase disclosed herein.
- a pharmaceutical composition comprising one or more Ranpirnase disclosed herein and/or one or more Amphinase disclosed herein, when administered to an individual, stimulates an anti-inflammatory response against the one or more viral strains causing a viral conjunctivitis.
- a pharmaceutical composition is a medicament for the treatment of a viral conjunctivitis disclosed herein.
- a one or more Ranpirnase disclosed herein and/or one or more Amphinase disclosed herein is used to manufacture a medicament for the treatment of a viral conjunctivitis disclosed herein.
- use of a Ranpirnase and/or Amphinase disclosed herein is in an amount sufficient to treats a viral conjunctivitis disclosed herein by reducing one or more physiological conditions or symptom associated with a viral conjunctivitis disclosed herein.
- a pharmaceutical composition disclosed herein comprises a single Ranpirnase and/or Amphinase disclosed herein. In one embodiment, a pharmaceutical composition disclosed herein comprises a plurality of Ranpirnases and/or Amphinases disclosed herein. In aspects of this embodiment, a pharmaceutical composition disclosed herein comprises, e.g., 1 , 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 , 12, 13, 14, or 15 Ranpirnases and/or Amphinases disclosed herein.
- a pharmaceutical composition disclosed herein comprises, e.g., at least 1 , at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 1 1 , at least 12, at least 13, at least 14, or at least Ranpirnases and/or Amphinases disclosed herein.
- a pharmaceutical composition disclosed herein comprises, e.g., at most 1 , at most 2, at most 3, at most 4, at most 5, at most 6, at most 7, at most 8, at most 9, at most 10, at most 11 , at most 12, at most 13, at most 14, or at most Ranpirnases and/or Amphinases disclosed herein.
- a pharmaceutical composition disclosed herein comprises, e.g., 1 to 2, 1 to 3, 1 to 4, 1 to 5, 1 to 6, 1 to 7, 1 to 8, 1 to 9, 1 to 10, 1 to 1 1 , 1 to 12, 1 to 13, 1 to 14, 1 to 15, 2 to 3, 2 to 4, 2 to 5, 2 to 6, 2 to 7, 2 to 8, 2 to 9, 2 to 10, 2 to 1 1 , 2 to 12, 2 to 13, 2 to 14, 2 to 15, 3 to 4, 3 to 5, 3 to 6, 3 to 7, 3 to 8, 3 to 9, 3 to 10, 3 to 11 , 3 to 12, 3 to 13, 3 to 14, 3 to 15, 4 to 5, 4 to 6, 4 to 7, 4 to 8, 4 to 9, 4 to 10, 4 to 1 1 , 4 to 12, 4 to 13, 4 to 14, 4 to 15, 5 to 6, 5 to 7, 5 to 8, 5 to 9, 5 to 10, 5 to 1 1 , 5 to 12, 5 to 13, 5 to 14, 5 to 15, 6 to 7, 6 to 8, 6 to 9, 6 to 10, 6 to 1 1 , 6 to 12, 6 to 13, 6 to 14, 6 to 15, 7 to 8, 7 to 9, 7 to 9, 7 to
- the amount of a Ranpirnase and/or Amphinase disclosed herein included in a pharmaceutical composition is an amount sufficient to elicit an appropriate anti-inflammatory response in the individual. Typically, this amount is also one that does not cause significant adverse side effects. Such amount will vary depending on which specific Ranpirnase and/or Amphinase is administered.
- An optimal amount for a particular pharmaceutical composition can be ascertained by standard studies involving observation of proinflammatory cytokine titers, anti-inflammatory cytokine titers, prostaglandin titers, reduction of one or more symptoms associated with a viral conjunctivitis, and other responses in individuals.
- a primary pharmaceutical composition course may include 1 , 2, 3 or 4 doses of a pharmaceutical composition, given at intervals optimal for providing an anti-inflammatory response.
- an effective and safe amount of a Ranpirnase and/or Amphinase disclosed herein included in a pharmaceutical composition varies from about 1 fg to 3,000 mg.
- an amount of a Ranpirnase and/or Amphinase disclosed herein included in a pharmaceutical composition may be, e.g., about 1 fg, about 2 fg, about 3 fg, about 4 fg, about 5 fg, about 6 fg, about 7 fg, about 8 fg, about 9 fg, about 10 fg, about 15 fg, about 20 fg, about 25 fg, about 30 fg, about 35 fg, about 40 fg, about 45 fg, about 50 fg, about 55 fg, about 60 fg, about 65 fg, about 70 fg, about 75 fg, about 80 fg, about 85 fg, about 90 fg, about 95 fg, about 100 fg, about 1 10 fg, about 120 fg, about 130 fg, about 140 fg, about 150 fg, about 160 fg, about 170 fg,
- an amount of a Ranpirnase and/or Amphinase disclosed herein included in a pharmaceutical composition may be, e.g., at least 1 fg, at least 2 fg, at least 3 fg, at least 4 fg, at least 5 fg, at least 6 fg, at least 7 fg, at least 8 fg, at least 9 fg, at least 10 fg, at least 15 fg, at least 20 fg, at least 25 fg, at least 30 fg, at least 35 fg, at least 40 fg, at least 45 fg, at least 50 fg, at least 55 fg, at least 60 fg, at least 65 fg, at least 70 fg, at least 75 fg, at least 80 fg, at least 85 fg, at least 90 fg, at least 95 fg, at least 100 fg, at least 110 fg, at least 120
- an amount of a Ranpirnase and/or Amphinase disclosed herein included in a pharmaceutical composition may be, e.g., at most 1 fg, at most 2 fg, at most 3 fg, at most 4 fg, at most 5 fg, at most 6 fg, at most 7 fg, at most 8 fg, at most 9 fg, at most 10 fg, at most 15 fg, at most 20 fg, at most 25 fg, at most 30 fg, at most 35 fg, at most 40 fg, at most 45 fg, at most 50 fg, at most 55 fg, at most 60 fg, at most 65 fg, at most 70 fg, at most 75 fg, at most 80 fg, at most 85 fg, at most 90 fg, at most 95 fg, at most 100 fg, at most 1 10 fg, at most
- an amount of a Ranpirnase and/or Amphinase disclosed herein included in a pharmaceutical composition may be in the range of, e.g., about 1 fg to about 10 fg, about 1 fg to about 20 fg, about 1 fg to about 30 fg, about 1 fg to about 40 fg, about 1 fg to about 50 fg, about 1 fg to about 60 fg, about 1 fg to about 70 fg, about 1 fg to about 80 fg, about 1 fg to about 90 fg, about 1 fg to about 100 fg, about 1 fg to about 110 fg, about 1 fg to about 120 fg, about 1 fg to about 130 fg, about 1 fg to about 140 fg, about 1 fg to about 150 fg, about 5 fg to about 10 fg, about 5 fg to about 20 f
- an amount of a Ranpirnase and/or Amphinase disclosed herein included in a pharmaceutical composition may be in the range of, e.g., about 100 fg to about 125 fg, about 100 fg to about 150 fg, about 100 fg to about 175 fg, about 100 fg to about 200 fg, about 100 fg to about 225 fg, about 100 fg to about 250 fg, about 100 fg to about 275 fg, about 100 fg to about 300 fg, about 100 fg to about 325 fg, about 100 fg to about 350 fg, about 100 fg to about 375 fg, about 100 fg to about 400 fg, about 100 fg to about 425 fg, about 100 fg to about 450 fg, about 100 fg to about 475 fg, about 100 fg to about 500 fg, about
- an amount of a Ranpirnase and/or Amphinase disclosed herein included in a pharmaceutical composition may be in the range of, e.g., about 250 fg to about 275 fg, about 250 fg to about 300 fg, about 250 fg to about 325 fg, about 250 fg to about 350 fg, about 250 fg to about 375 fg, about 250 fg to about 400 fg, about 250 fg to about 425 fg, about 250 fg to about 450 fg, about 250 fg to about 475 fg, about 250 fg to about 500 fg, about 250 fg to about 525 fg, about 250 fg to about 550 fg, about 250 fg to about 575 fg, about 250 fg to about 600 fg, about 250 fg to about 625 fg, about 250 fg to about 650 fg
- an amount of a Ranpirnase and/or Amphinase disclosed herein included in a pharmaceutical composition may be in the range of, e.g., about 500 fg to about 525 fg, about 500 fg to about 550 fg, about 500 fg to about 575 fg, about 500 fg to about 600 fg, about 500 fg to about 625 fg, about 500 fg to about 650 fg, about 500 fg to about 675 fg, about 500 fg to about 700 fg, about 500 fg to about 725 fg, about 500 fg to about 750 fg, about 500 fg to about 775 fg, about 500 fg to about 800 fg, about 500 fg to about 825 fg, about 500 fg to about 850 fg, about 500 fg to about 875 fg, about 500 fg to about 900
- an amount of a Ranpirnase and/or Amphinase disclosed herein included in a pharmaceutical composition may be, e.g., about 1 ng, about 2 ng, about 3 ng, about 4 ng, about 5 ng, about 6 ng, about 7 ng, about 8 ng, about 9 ng, about 10 ng, about 15 ng, about 20 ng, about 25 ng, about 30 ng, about 35 ng, about 40 ng, about 45 ng, about 50 ng, about 55 ng, about 60 ng, about 65 ng, about 70 ng, about 75 ng, about 80 ng, about 85 ng, about 90 ng, about 95 ng, about 100 ng, about 1 10 ng, about 120 ng, about 130 ng, about 140 ng, about 150 ng, about 160 ng, about 170 ng, about 180 ng, about 190 ng, about 200 ng, about 210 ng, about 220 ng, about 230
- an amount of a Ranpirnase and/or Amphinase disclosed herein included in a pharmaceutical composition may be, e.g., at least 1 ng, at least 2 ng, at least 3 ng, at least 4 ng, at least 5 ng, at least 6 ng, at least 7 ng, at least 8 ng, at least 9 ng, at least 10 ng, at least 15 ng, at least 20 ng, at least 25 ng, at least 30 ng, at least 35 ng, at least 40 ng, at least 45 ng, at least 50 ng, at least 55 ng, at least 60 ng, at least 65 ng, at least 70 ng, at least 75 ng, at least 80 ng, at least 85 ng, at least 90 ng, at least 95 ng, at least 100 ng, at least 1 10 ng, at least 120 ng, at least 130 ng, at least 140 ng, at least 150 ng, at least 160 ng, at least
- an amount of a Ranpirnase and/or Amphinase disclosed herein included in a pharmaceutical composition may be, e.g., at most 1 ng, at most 2 ng, at most 3 ng, at most 4 ng, at most 5 ng, at most 6 ng, at most 7 ng, at most 8 ng, at most 9 ng, at most 10 ng, at most 15 ng, at most 20 ng, at most 25 ng, at most 30 ng, at most 35 ng, at most 40 ng, at most 45 ng, at most 50 ng, at most 55 ng, at most 60 ng, at most 65 ng, at most 70 ng, at most 75 ng, at most 80 ng, at most 85 ng, at most 90 ng, at most 95 ng, at most 100 ng, at most 110 ng, at most 120 ng, at most 130 ng, at most 140 ng, at most 150 ng, at most 160 ng, at most
- an amount of a Ranpirnase and/or Amphinase disclosed herein included in a pharmaceutical composition may be in the range of, e.g., about 1 ng to about 10 ng, about 1 ng to about 20 ng, about 1 ng to about 30 ng, about 1 ng to about 40 ng, about 1 ng to about 50 ng, about 1 ng to about 60 ng, about 1 ng to about 70 ng, about 1 ng to about 80 ng, about 1 ng to about 90 ng, about 1 ng to about 100 ng, about 1 ng to about 1 10 ng, about 1 ng to about 120 ng, about 1 ng to about 130 ng, about 1 ng to about 140 ng, about 1 ng to about 150 ng, about 5 ng to about 10 ng, about 5 ng to about 20 ng, about 5 ng to about 30 ng, about 5 ng to about 40 ng, about 5 ng to about 50 ng, about
- an amount of a Ranpirnase and/or Amphinase disclosed herein included in a pharmaceutical composition may be in the range of, e.g., about 100 ng to about 125 ng, about 100 ng to about 150 ng, about 100 ng to about 175 ng, about 100 ng to about 200 ng, about 100 ng to about 225 ng, about 100 ng to about 250 ng, about 100 ng to about 275 ng, about 100 ng to about 300 ng, about 100 ng to about 325 ng, about 100 ng to about 350 ng, about 100 ng to about 375 ng, about 100 ng to about 400 ng, about 100 ng to about 425 ng, about 100 ng to about 450 ng, about 100 ng to about 475 ng, about 100 ng to about 500 ng, about 100 ng to about 525 ng, about 100 ng to about 550 ng, about 100 ng to about 575 ng,
- an amount of a Ranpirnase and/or Amphinase disclosed herein included in a pharmaceutical composition may be in the range of, e.g., about 250 ng to about 275 ng, about 250 ng to about 300 ng, about 250 ng to about 325 ng, about 250 ng to about 350 ng, about 250 ng to about 375 ng, about 250 ng to about 400 ng, about 250 ng to about 425 ng, about 250 ng to about 450 ng, about 250 ng to about 475 ng, about 250 ng to about 500 ng, about 250 ng to about 525 ng, about 250 ng to about 550 ng, about 250 ng to about 575 ng, about 250 ng to about 600 ng, about 250 ng to about 625 ng, about 250 ng to about 650 ng, about 250 ng to about 675 ng, about 250 ng to about 700 ng, about 250 ng to about 725 ng
- an amount of a Ranpirnase and/or Amphinase disclosed herein included in a pharmaceutical composition may be in the range of, e.g., about 500 ng to about 525 ng, about 500 ng to about 550 ng, about 500 ng to about 575 ng, about 500 ng to about 600 ng, about 500 ng to about 625 ng, about 500 ng to about 650 ng, about 500 ng to about 675 ng, about 500 ng to about 700 ng, about 500 ng to about 725 ng, about 500 ng to about 750 ng, about 500 ng to about 775 ng, about 500 ng to about 800 ng, about 500 ng to about 825 ng, about 500 ng to about 850 ng, about 500 ng to about 875 ng, about 500 ng to about 900 ng, about 500 ng to about 925 ng, about 500 ng to about 950 ng, about 500 ng to about 9
- an amount of a Ranpirnase and/or Amphinase disclosed herein included in a pharmaceutical composition may be, e.g., about 1 pg, about 2 pg, about 3 pg, about 4 pg, about 5 pg, about 6 pg, about 7 pg, about 8 pg, about 9 pg, about 10 pg, about 15 pg, about 20 pg, about 25 pg, about 30 pg, about 35 pg, about 40 pg, about 45 pg, about 50 pg, about 55 pg, about 60 pg, about 65 pg, about 70 pg, about 75 pg, about 80 pg, about 85 pg, about 90 pg, about 95 pg, about 100 pg, about 1 10 pg, about 120 pg, about 130 pg, about 140 pg, about 150 pg, about 160 pg, about 170
- an amount of a Ranpirnase and/or Amphinase disclosed herein included in a pharmaceutical composition may be, e.g., at least 1 pg, at least 2 pg, at least 3 pg, at least 4 pg, at least 5 pg, at least 6 pg, at least 7 pg, at least 8 pg, at least 9 pg, at least 10 pg, at least 15 pg, at least 20 pg, at least 25 pg, at least 30 pg, at least 35 pg, at least 40 pg, at least 45 pg, at least 50 pg, at least 55 pg, at least 60 pg, at least 65 pg, at least 70 pg, at least 75 pg, at least 80 pg, at least 85 pg, at least 90 pg, at least 95 pg, at least 100 pg, at least 110 pg, at least 120 .
- an amount of a Ranpirnase and/or Amphinase disclosed herein included in a pharmaceutical composition may be, e.g., at most 1 pg, at most 2 pg, at most 3 pg, at most 4 pg, at most 5 pg, at most 6 pg, at most 7 pg, at most 8 pg, at most 9 pg, at most 10 pg, at most 15 pg, at most 20 pg, at most 25 pg, at most 30 pg, at most 35 pg, at most 40 pg, at most 45 pg, at most 50 pg, at most 55 pg, at most 60 pg, at most 65 pg, at most 70 pg, at most 75 pg, at most 80 pg, at most 85 pg, at most 90 pg, at most 95 pg, at most 100 pg, at most 1 10 pg, at most
- an amount of a Ranpirnase and/or Amphinase disclosed herein included in a pharmaceutical composition may be in the range of, e.g., about 1 pg to about 10 pg, about 1 pg to about 20 pg, about 1 pg to about 30 pg, about 1 pg to about 40 pg, about 1 pg to about 50 pg, about 1 pg to about 60 pg, about 1 pg to about 70 pg, about 1 pg to about 80 pg, about 1 pg to about 90 pg, about 1 pg to about 100 pg, about 1 pg to about 1 10 pg, about 1 pg to about 120 pg, about 1 pg to about 130 pg, about 1 pg to about 140 pg, about 1 pg to about 150 pg, about 5 pg to about 10 pg, about 5 pg to about 20 pg, about 1 pg to about 30
- an amount of a Ranpirnase and/or Amphinase disclosed herein included in a pharmaceutical composition may be in the range of, e.g., about 100 pg to about 125 pg, about 100 pg to about 150 pg, about 100 pg to about 175 pg, about 100 pg to about 200 pg, about 100 pg to about 225 pg, about 100 pg to about 250 pg, about 100 pg to about 275 pg, about 100 pg to about 300 pg, about 100 pg to about 325 pg, about 100 pg to about 350 pg, about 100 pg to about 375 pg, about 100 pg to about 400 pg, about 100 pg to about 425 pg, about 100 pg to about 450 pg, about 100 pg to about 475 pg, about 100 pg to about 500 pg, about
- an amount of a Ranpirnase and/or Amphinase disclosed herein included in a pharmaceutical composition may be in the range of, e.g., about 250 pg to about 275 pg, about 250 pg to about 300 pg, about 250 pg to about 325 pg, about 250 pg to about 350 pg, about 250 pg to about 375 pg, about 250 pg to about 400 pg, about 250 pg to about 425 pg, about 250 pg to about 450 pg, about 250 pg to about 475 pg, about 250 pg to about 500 pg, about 250 pg to about 525 pg, about 250 pg to about 550 pg, about 250 pg to about 575 pg, about 250 pg to about 600 pg, about 250 pg to about 625 pg, about 250 pg to about 650 pg
- an amount of a Ranpirnase and/or Amphinase disclosed herein included in a pharmaceutical composition may be in the range of, e.g., about 500 pg to about 525 pg, about 500 pg to about 550 pg, about 500 pg to about 575 pg, about 500 pg to about 600 pg, about 500 pg to about 625 pg, about 500 pg to about 650 pg, about 500 pg to about 675 pg, about 500 pg to about 700 ig, about 500 ig to about 725 ig, about 500 ig to about 750 ig, about 500 ig to about 775 pg, about 500 [ig to about 800 [ig, about 500 pg to about 825 [ig, about 500 [ig to about 850 [ig, about 500 pg to about 875 [ig, about 500 [ig to about 900
- an amount of a Ranpirnase and/or Amphinase disclosed herein included in a pharmaceutical composition may be, e.g., about 1 mg, about 2 mg, about 3 mg, about 4 mg, about 5 mg, about 6 mg, about 7 mg, about 8 mg, about 9 mg, about 10 mg, about 15 mg, about 20 mg, about 25 mg, about 30 mg, about 35 mg, about 40 mg, about 45 mg, about 50 mg, about 55 mg, about 60 mg, about 65 mg, about 70 mg, about 75 mg, about 80 mg, about 85 mg, about 90 mg, about 95 mg, about 100 mg, about 1 10 mg, about 120 mg, about 130 mg, about 140 mg, about 150 mg, about 160 mg, about 170 mg, about 180 mg, about 190 mg, about 200 mg, about 210 mg, about 220 mg, about 230 mg, about 240 mg, about 250 mg, 260 mg, about 270 mg, about 280 mg, about 290 mg, about 300 mg, about 310 mg, about
- an amount of a Ranpirnase and/or Amphinase disclosed herein included in a pharmaceutical composition may be, e.g., at least 1 mg, at least 2 mg, at least 3 mg, at least 4 mg, at least 5 mg, at least 6 mg, at least 7 mg, at least 8 mg, at least 9 mg, at least 10 mg, at least 15 mg, at least 20 mg, at least 25 mg, at least 30 mg, at least 35 mg, at least 40 mg, at least 45 mg, at least 50 mg, at least 55 mg, at least 60 mg, at least 65 mg, at least 70 mg, at least 75 mg, at least 80 mg, at least 85 mg, at least 90 mg, at least 95 mg, at least 100 mg, at least 1 10 mg, at least 120 mg, at least 130 mg, at least 140 mg, at least 150 mg, at least 160 mg, at least 170 mg, at least 180 mg, at least 190 mg, at least 200 mg, at least 210 mg, at least 220 mg, at least
- an amount of a Ranpirnase and/or Amphinase disclosed herein included in a pharmaceutical composition may be, e.g., at most 1 mg, at most 2 mg, at most 3 mg, at most 4 mg, at most 5 mg, at most 6 mg, at most 7 mg, at most 8 mg, at most 9 mg, at most 10 mg, at most 15 mg, at most 20 mg, at most 25 mg, at most 30 mg, at most 35 mg, at most 40 mg, at most 45 mg, at most 50 mg, at most 55 mg, at most 60 mg, at most 65 mg, at most 70 mg, at most 75 mg, at most 80 mg, at most 85 mg, at most 90 mg, at most 95 mg, at most 100 mg, at most 1 10 mg, at most 120 mg, at most 130 mg, at most 140 mg, at most 150 mg, at most 160 mg, at most 170 mg, at most 180 mg, at most 190 mg, at most 200 mg, at most 210 mg, at most 220 mg, at
- an amount of a Ranpirnase and/or Amphinase disclosed herein included in a pharmaceutical composition may be in the range of, e.g., about 1 mg to about 10 mg, about 1 mg to about 20 mg, about 1 mg to about 30 mg, about 1 mg to about 40 mg, about 1 mg to about 50 mg, about 1 mg to about 60 mg, about 1 mg to about 70 mg, about 1 mg to about 80 mg, about 1 mg to about 90 mg, about 1 mg to about 100 mg, about 1 mg to about 110 mg, about 1 mg to about 120 mg, about 1 mg to about 130 mg, about 1 mg to about 140 mg, about 1 mg to about 150 mg, about 5 mg to about 10 mg, about 5 mg to about 20 mg, about 5 mg to about 30 mg, about 5 mg to about 40 mg, about 5 mg to about 50 mg, about 5 mg to about 60 mg, about 5 mg to about 70 mg, about 5 mg to about 80 mg, about 5 mg to about 90 mg, about 5 mg to about 100 mg, about 5 mg to about 10 mg, about 1 mg to about
- an amount of a Ranpirnase and/or Amphinase disclosed herein included in a pharmaceutical composition may be in the range of, e.g., about 100 mg to about 125 mg, about 100 mg to about 150 mg, about 100 mg to about 175 mg, about 100 mg to about 200 mg, about 100 mg to about 225 mg, about 100 mg to about 250 mg, about 100 mg to about 275 mg, about 100 mg to about 300 mg, about 100 mg to about 325 mg, about 100 mg to about 350 mg, about 100 mg to about 375 mg, about 100 mg to about 400 mg, about 100 mg to about 425 mg, about 100 mg to about 450 mg, about 100 mg to about 475 mg, about 100 mg to about 500 mg, about 100 mg to about 525 mg, about 100 mg to about 550 mg, about 100 mg to about 575 mg, about 100 mg to about 600 mg, about 125 mg to about 150 mg, about 125 mg to about 175 mg, about 125 mg to about 200 mg, about
- an amount of a Ranpirnase and/or Amphinase disclosed herein included in a pharmaceutical composition may be in the range of, e.g., about 250 mg to about 275 mg, about 250 mg to about 300 mg, about 250 mg to about 325 mg, about 250 mg to about 350 mg, about 250 mg to about 375 mg, about 250 mg to about 400 mg, about 250 mg to about 425 mg, about 250 mg to about 450 mg, about 250 mg to about 475 mg, about 250 mg to about 500 mg, about 250 mg to about 525 mg, about 250 mg to about 550 mg, about 250 mg to about 575 mg, about 250 mg to about 600 mg, about 250 mg to about 625 mg, about 250 mg to about 650 mg, about 250 mg to about 675 mg, about 250 mg to about 700 mg, about 250 mg to about 725 mg, about 250 mg to about 750 mg, about 250 mg to about 775 mg, about 250 mg to about 800 mg, about 250 mg to about 825 mg, about 250 mg to about 275 mg, about 250 mg to
- an amount of a Ranpirnase and/or Amphinase disclosed herein included in a pharmaceutical composition may be in the range of, e.g., about 500 mg to about 525 mg, about 500 mg to about 550 mg, about 500 mg to about 575 mg, about 500 mg to about 600 mg, about 500 mg to about 625 mg, about 500 mg to about 650 mg, about 500 mg to about 675 mg, about 500 mg to about 700 mg, about 500 mg to about 725 mg, about 500 mg to about 750 mg, about 500 mg to about 775 mg, about 500 mg to about 800 mg, about 500 mg to about 825 mg, about 500 mg to about 850 mg, about 500 mg to about 875 mg, about 500 mg to about 900 mg, about 500 mg to about 925 mg, about 500 mg to about 950 mg, about 500 mg to about 975 mg, about 500 mg to about 1 ,000 mg, about 600 mg to about 625 mg, about 600 mg to about 650 mg, about 600 mg to about
- a pharmaceutical composition disclosed herein may optionally include a pharmaceutically- acceptable carrier that facilitates processing of an active ingredient into pharmaceutically-acceptable compositions.
- a pharmaceutically-acceptable carrier is synonymous with “pharmacological carrier” and means any carrier that has substantially no long term or permanent detrimental effect when administered and encompasses terms such as "pharmacologically acceptable vehicle, stabilizer, diluent, additive, auxiliary or excipient.”
- Such a carrier generally is mixed with an active compound or permitted to dilute or enclose the active compound and can be a solid, semi-solid, or liquid agent. It is understood that the active ingredients can be soluble or can be delivered as a suspension in the desired carrier or diluent.
- aqueous media such as, e.g., water, saline, glycine, hyaluronic acid and the like
- solid carriers such as, e.g., mannitol, lactose, starch, magnesium stearate, sodium saccharin, talcum, cellulose, glucose, sucrose, magnesium carbonate, and the like
- solvents dispersion media; coatings; antibacterial and antifungal agents; isotonic and absorption delaying agents; or any other inactive ingredient.
- Selection of a pharmacologically acceptable carrier can depend on the mode of administration.
- any pharmacologically acceptable carrier is incompatible with the active ingredient, its use in pharmaceutically acceptable compositions is contemplated.
- Non-limiting examples of specific uses of such pharmaceutical carriers can be found in Pharmaceutical Dosage Forms and Drug Delivery Systems (Howard C. Ansel et al., eds., Lippincott Williams & Wilkins Publishers, 7th ed. 1999); REMINGTON: THE SCIENCE AND PRACTICE OF PHARMACY (Alfonso R. Gennaro ed., Lippincott, Williams & Wilkins, 20th ed. 2000); Goodman & Gilman's The Pharmacological Basis of Therapeutics (Joel G.
- a pharmaceutical composition disclosed herein can optionally include, without limitation, other pharmaceutically acceptable components (or pharmaceutical components), including, without limitation, buffers, preservatives, tonicity adjusters, salts, antioxidants, osmolality adjusting agents, physiological substances, pharmacological substances, bulking agents, emulsifying agents, wetting agents, sweetening or flavoring agents, and the like.
- buffers include, without limitation, acetate buffers, citrate buffers, phosphate buffers, neutral buffered saline, phosphate buffered saline and borate buffers.
- antioxidants include, without limitation, sodium metabisulfite, sodium thiosulfate, acetylcysteine, butylated hydroxyanisole and butylated hydroxytoluene.
- Useful preservatives include, without limitation, benzalkonium chloride, chlorobutanol, thimerosal, phenylmercuric acetate, phenylmercuric nitrate, a stabilized oxy chloro composition, such as, e.g., PURITE ® and chelants, such as, e.g., DTPA or DTPA- bisamide, calcium DTPA, and CaNaDTPA-bisamide. Many of these preservatives have bactericidal properties.
- Tonicity adjustors useful in a pharmaceutical composition include, without limitation, salts such as, e.g., sodium chloride, potassium chloride, mannitol or glycerin and other pharmaceutically acceptable tonicity adjustor.
- the pharmaceutical composition may be provided as a salt and can be formed with many acids, including but not limited to, hydrochloric, sulfuric, acetic, lactic, tartaric, malic, succinic, etc. Salts tend to be more soluble in aqueous or other protonic solvents than are the corresponding free base forms. It is understood that these and other substances known in the art of pharmacology can be included in a pharmaceutical composition.
- a pharmaceutical composition disclosed herein may be formulated for either local or systemic delivery using topical, ophthalmic, enteral or parenteral routes of administration.
- a pharmaceutical composition disclosed herein may be produced as a liquid formulation, a semi-solid formulation, or a solid formulation.
- a formulation disclosed herein can be produced in a manner to form one phase, such as, e.g., an oil or a solid.
- a formulation disclosed herein can be produced in a manner to form two phase, such as, e.g., a colloidal formulation.
- a pharmaceutical composition disclosed herein intended for such administration may be prepared according to any method known to the art for the manufacture of pharmaceutical compositions.
- Liquid formulations suitable for topical and ophthalmologic administration include, without limitation, solutions and emulsions.
- Semi-solid formulations suitable for topical and ophthalmologic administration include, without limitation, ointments, creams, salves, foams, and gels.
- Solid formulations suitable for topical and ophthalmologic administration include, without limitation, gel implants, solid sol implants and solid implants.
- a formulation disclosed herein may be a simple one or as part of a more complex drug delivery system. Regardless of the formulation, a Ranpirnase and/or Amphinase disclosed herein as well as the pharmaceutically acceptable excipients and components must be compatible with an ophthalmic formulation because the eye is very sensitive to irritants. This includes factors such as osmolarity, pH, temperature and others.
- a formulation disclosed herein could include pre-optimized ocular wetting solutions such as Refresh artificial tears or other over-the-counter (OTC) tears available today.
- a Ranpirnase and/or Amphinase disclosed herein may be formulated by itself in a pharmaceutical composition, or may be formulated together with one or more other therapeutic compounds disclosed herein in a single pharmaceutical composition.
- a Ranpirnase and/or Amphinase disclosed herein may be formulated in a controlled release delivery platform including a sustained release formulation and an extended release formulation.
- the ocular surface is a tough target tissue to administer a drug to as tear production immediately dilutes any active ingredient. Further, blinking provides another source of immediately dilution and removal of any active ingredient being delivered.
- the use of a controlled release delivery platform adheres of the ocular surface to ensure that a Ranpirnase and/or Amphinase disclosed herein remains for a time sufficient to deliver the required dose necessary for therapeutic effect.
- Such controlled release delivery platform can improve the delivery kinetics of a Ranpirnase and/or Amphinase disclosed herein by releasing in a time controlled fashion, potentially minimizing the number of instillations required over a course of treatment.
- An extended release formulation refers to the release of a Ranpirnase and/or Amphinase disclosed herein over a period of time of less than about seven days.
- a sustained release formulation refers to the release of a Ranpirnase and/or Amphinase disclosed herein over a period of about seven days or more.
- a sustained release formulation releases a Ranpirnase and/or Amphinase disclosed herein or a pharmaceutical composition disclosed herein with substantially zero order release kinetics over a period of, e.g., about 7 days, about 15 days after administration, about 30 days, about 45 days, about 60 days, about 75 days, or about 90 days after administration.
- a sustained release formulation releases a Ranpirnase and/or Amphinase disclosed herein or a pharmaceutical composition disclosed herein with substantially zero order release kinetics over a period of, e.g., at least 7 days, at least 15 days, at least 30 days, at least 45 days, at least 60 days, at least 75 days, or at least 90 days after administration.
- a sustained release formulation releases a Ranpirnase and/or Amphinase disclosed herein or a pharmaceutical composition disclosed herein with substantially first order release kinetics over a period of, e.g., about 7 days, about 15 days after administration, about 30 days, about 45 days, about 60 days, about 75 days, or about 90 days after administration.
- a sustained release formulation releases a Ranpirnase and/or Amphinase disclosed herein or a pharmaceutical composition disclosed herein with substantially first order release kinetics over a period of, e.g., at least 7 days, at least 15 days, at least 30 days, at least 45 days, at least 60 days, at least 75 days, or at least 90 days after administration.
- an extended release formulation releases a Ranpirnase and/or Amphinase disclosed herein or a pharmaceutical composition disclosed herein with substantially zero order release kinetics over a period of, e.g., about 1 day, about 2 days, about 3 days, about 4 days, about 5 days, about 6 days, or about 7 days after administration.
- an extended release formulation releases a Ranpirnase and/or Amphinase disclosed herein or a pharmaceutical composition disclosed herein with substantially zero order release kinetics over a period of, e.g., at most 1 day, at most 2 days, at most 3 days, at most 4 days, at most 5 days, at most 6 days, or at most 7 days after administration.
- an extended release formulation releases a Ranpirnase and/or Amphinase disclosed herein or a pharmaceutical composition disclosed herein with substantially first order release kinetics over a period of, e.g., about 1 day, about 2 days, about 3 days, about 4 days, about 5 days, about 6 days, or about 7 days after administration.
- an extended release formulation releases a Ranpirnase and/or Amphinase disclosed herein or a pharmaceutical composition disclosed herein with substantially first order release kinetics over a period of, e.g. , at most 1 day, at most 2 days, at most 3 days, at most 4 days, at most 5 days, at most 6 days, or at most 7 days after administration.
- aspects of the present specification disclose, in part, a method of treating an individual with a viral conjunctivitis.
- the method comprises the step of administering to an individual in need thereof a Ranpirnase and/or Amphinase disclosed herein or a pharmaceutical composition disclosed herein, wherein administration reduces a symptom associated with the viral conjunctivitis, thereby treating the individual.
- Other aspects of the present specification disclose, in part, use of a Ranpirnase and/or Amphinase disclosed herein in the treatment an individual with a viral conjunctivitis.
- aspects of the present specification disclose, in part, treating an individual suffering from a viral conjunctivitis.
- the term “treating,” refers to reducing or eliminating in an individual a clinical symptom of a viral conjunctivitis; or delaying or preventing in an individual the onset of a clinical symptom of a viral conjunctivitis.
- the term "treating" can mean reducing a symptom of a condition characterized by a viral conjunctivitis by, e.g., at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90% at least 95%, or at least 100%.
- the actual symptoms associated with a viral conjunctivitis are well known and can be determined by a person of ordinary skill in the art by taking into account factors, including, without limitation, the duration of the viral conjunctivitis, the particular viral pathogen, and/orthe severity of the viral conjunctivitis.
- Non-limiting examples of symptoms associated with a viral conjunctivitis disclosed herein include scleral redness, scleral swelling, scleral leakage, inner eyelid redness, inner eyelid swelling, inner eyelid leakage, ocular itching (itchy eyes), foreign body sensation (gritty or scratchy eyes), burning eyes, painful eyes, blurred vision, increased sensitivity to light or photophobia, subepithelial infiltrates, increased tear production, watery discharge, mucopurulent discharge and eyelash crusting.
- Those of skill in the art will know the appropriate symptoms or indicators associated with a specific type of viral conjunctivitis and will know how to determine if an individual is a candidate for treatment as disclosed herein.
- aspects of the present disclosure comprise, in part, a viral conjunctivitis.
- Viral conjunctivitis is the most common infectious eye condition today. It is estimated to comprise up to 70% of total conjunctivitis cases seen annually.
- a viral conjunctivitis disclosed herein includes an epidemic keratoconjunctivitis, a pharingoconjunctival fever, a nonspecific sporadic follicular conjunctivitis, or a chronic papillary conjunctivitis. Of the virus families that cause human disease, adenoviruses are responsible for up to 90% of the cases.
- viruses that can also be responsible for conjunctival infection include herpes simplex virus (HSV), varicella-zoster virus (VZV), picornavirus (enterovirus 70, Coxsackie A24), and poxvirus (Molluscum contagiosum virus, vaccinia).
- HSV herpes simplex virus
- VZV varicella-zoster virus
- picornavirus enterovirus 70, Coxsackie A24
- poxvirus Molluscum contagiosum virus, vaccinia
- Adenoviruses members of the family Adenoviridae are medium-sized (90 to 100 nm), non- enveloped viruses with an icosahedral nucleocapsid containing a double-stranded DNA genome. Adenoviruses have a broad range of vertebrate hosts. About 60 distinct adenoviral serotypes have been found to cause a wide range of illnesses in humans, from mild respiratory infections in young children (known as the common cold) to life-threatening multi-organ disease in people with a weakened immune system.
- adenovirus serotypes 3, 4, 7, 8, 11 , 13, 19 and 37 appear to be the primary causative agents, although other adenovirus serotypes may also cause viral conjunctivitis.
- Adenovirus serotypes 3, 7 and 1 1 are classified as Human adenovirus B; serotype 8, 13, 19 and 37 are classified as Human adenovirus D; and serotype 4 is classified as Human adenovirus E.
- every individual is considered to be susceptible to infection.
- conjunctival viral infections initiate a strong immune response. The ability to regulate this response will aid in reducing many of the clinical symptoms associated with viral conjunctivitis.
- EKC Epidemic Keratoconjunctivitis
- Corneal involvement can occur in the form of diffuse, fine, and/or superficial keratitis, epithelial defects, and even subepithelial opacities. In 20-50% of cases, corneal opacities can persist for a few weeks to months. This phenomenon can significantly decrease visual acuity and cause glare symptoms. Treatment is mostly intended to control symptoms through the use of cold compresses and artificial tears. Antivirals (such as cidofovir) and cyclosporine eye drops were tested clinically but no definitive benefit was observed. In very specific cases with severe membranous conjunctivitis, mild topical corticosteroids can be used to control inflammation.
- EKC is usually a self-limiting disease.
- the incubation period is 2-14 days, and the person may remain infectious for 10-14 days after symptoms develop. Symptoms tend to last for 7-21 days.
- the fellow eye tends to be involved in more than 50% of the cases within 7 days of onset.
- the signs and symptoms are typically less severe in the fellow eye. It tends to resolve spontaneously without significant complications.
- the patient is usually confined to their homes in effort not to propagate the infection. In rare cases, conjunctival scarring and conjunctival adhesions can occur secondary to membranous conjunctivitis.
- EKC epidemics tend to occur in closed institutions (such as schools, hospitals, camps, nursing homes, workplaces). Direct contact with eye secretions is the major mode of transmission. Other possible methods of transmission are air droplets and possibly swimming pools. Adenovirus can be recovered from the eye for as long as 14 days after the onset of clinical symptoms. Also, the role of medical clinics in spreading the disease is well documented. Many epidemics have been initiated in ophthalmology outpatient clinics by direct contact with contaminated diagnostic instruments.
- Some of the reasons behind the infectious transmission of EKC in hospitals and clinics include the fact that: (1) the virus can remain "viable” for 5 weeks; (2) the virus is resistant to standard disinfectants, such as 70% isopropyl alcohol and ammonia; and (3) the virus sheds from the eye three (3) days before and fourteen (14) days after symptom onset.
- Pharingoconjunctival Fever is an acute and highly infectious illness characterized by its associated systemic manifestations, such as fever, pharyngitis, acute follicular conjunctivitis, and regional lymphoid hyperplasia with tender, enlarged preauricular adenopathy. Patients experience a sudden or gradual onset of fever ranging from 100-104°F, lasting up to 10 days. Myalgia, malaise, and Gl disturbances frequently are associated with the fever. The pharyngitis may be mild or quite painful. Initial symptoms of conjunctivitis range from slight itching and burning to marked irritation and tearing, but little photophobia. Swelling of the lids may occur within 48 hours.
- Signs of disease include epiphora, conjunctival hyperemia (redness) and chemosis, subconjunctival hemorrhage, follicular or mild papillary conjunctival reaction, and eyelid edema. Mild crusting of the lids and discharge may occur. PCF most frequently is bilateral, with one eye typically having onset 1-3 days prior to the second eye. With bilateral disease, the first eye generally is affected more severely.
- Viral conjunctivitis has two main attributes that need mitigation, the presence and replication of virus and the host immune response that leads to clinical symptoms. For a successful therapy, addressing only one of these two facets is not enough.
- a Ranpirnase or Amphinase disclosed herein appear to have both antiviral and immunomodulatory mechanisms of action.
- the present specification discloses a method or use of treating a viral conjunctivitis cause by a Human adenovirus B in an individual in need thereof with by administering to the individual a Ranpirnase and/or Amphinase disclosed herein or a pharmaceutical composition disclosed herein, wherein administration reduces a symptom associated with the viral conjunctivitis, thereby treating the individual.
- the method disclosed herein treats a viral conjunctivitis cause by Human adenovirus B serotype 3, Human adenovirus B serotype 7, Human adenovirus B serotype 1 1 , or any combination thereof.
- the present specification discloses a method or use of treating an epidemic keratoconjunctivitis cause by a Human adenovirus B in an individual in need thereof with by administering to the individual a Ranpirnase and/or Amphinase disclosed herein or a pharmaceutical composition disclosed herein, wherein administration reduces a symptom associated with the viral conjunctivitis, thereby treating the individual.
- the method disclosed herein treats an epidemic keratoconjunctivitis cause by Human adenovirus B serotype 3, Human adenovirus B serotype 7, Human adenovirus B serotype 1 1 , or any combination thereof.
- the present specification discloses a method or use of treating a pharyngoconjunctival fever cause by a Human adenovirus B in an individual in need thereof with by administering to the individual a Ranpirnase and/or Amphinase disclosed herein or a pharmaceutical composition disclosed herein, wherein administration reduces a symptom associated with the viral conjunctivitis, thereby treating the individual.
- the method disclosed herein treats a pharyngoconjunctival fever cause by Human adenovirus B serotype 3, Human adenovirus B serotype 7, Human adenovirus B serotype 11 , or any combination thereof.
- the present specification discloses a method or use of treating a viral conjunctivitis cause by a Human adenovirus D in an individual in need thereof with by administering to the individual a Ranpirnase and/or Amphinase disclosed herein or a pharmaceutical composition disclosed herein, wherein administration reduces a symptom associated with the viral conjunctivitis, thereby treating the individual.
- the method disclosed herein treats a viral conjunctivitis cause by Human adenovirus D serotype 8, Human adenovirus D serotype 13, Human adenovirus D serotype 19, Human adenovirus D serotype 37, or any combination thereof.
- the present specification discloses a method or use of treating an epidemic keratoconjunctivitis cause by a Human adenovirus D in an individual in need thereof with by administering to the individual a Ranpirnase and/or Amphinase disclosed herein or a pharmaceutical composition disclosed herein, wherein administration reduces a symptom associated with the viral conjunctivitis, thereby treating the individual.
- the method disclosed herein treats an epidemic keratoconjunctivitis cause by Human adenovirus D serotype 8, Human adenovirus D serotype 13, Human adenovirus D serotype 19, Human adenovirus D serotype 37, or any combination thereof.
- the present specification discloses a method or use of treating a pharyngoconjunctival fever cause by a Human adenovirus D in an individual in need thereof with by administering to the individual a Ranpirnase and/or Amphinase disclosed herein or a pharmaceutical composition disclosed herein, wherein administration reduces a symptom associated with the viral conjunctivitis, thereby treating the individual.
- the method disclosed herein treats a pharyngoconjunctival fever cause by Human adenovirus D serotype 8, Human adenovirus D serotype 13, Human adenovirus D serotype 19, Human adenovirus D serotype 37, or any combination thereof.
- the present specification discloses a method or use of treating a viral conjunctivitis cause by a Human adenovirus E in an individual in need thereof with by administering to the individual a Ranpirnase and/or Amphinase disclosed herein or a pharmaceutical composition disclosed herein, wherein administration reduces a symptom associated with the viral conjunctivitis, thereby treating the individual.
- the method disclosed herein treats a viral conjunctivitis cause by Human adenovirus E serotype 4.
- the present specification discloses a method or use of treating an epidemic keratoconjunctivitis cause by a Human adenovirus E in an individual in need thereof with by administering to the individual a Ranpirnase and/or Amphinase disclosed herein or a pharmaceutical composition disclosed herein, wherein administration reduces a symptom associated with the viral conjunctivitis, thereby treating the individual.
- the method disclosed herein treats an epidemic keratoconjunctivitis cause by Human adenovirus E serotype 4.
- the present specification discloses a method or use of treating a pharyngoconjunctival fever cause by a Human adenovirus E in an individual in need thereof by administering the individual a Ranpirnase and/or Amphinase disclosed herein or a pharmaceutical composition disclosed herein, wherein administration reduces a symptom associated with the viral conjunctivitis, thereby treating the individual.
- the method disclosed herein treats a pharyngoconjunctival fever cause by Human adenovirus E serotype 4.
- the present specification discloses a method or use of reducing or suppressing a level of virus or viral titer in an individual in need thereof by administering to the individual a Ranpirnase and/or Amphinase disclosed herein or a pharmaceutical composition disclosed herein, wherein administration reduces or suppresses a level of virus or viral titer.
- a virus whose level or viral titer is reduced or suppressed is a Human adenovirus B, a Human adenovirus D, Human adenovirus E, or any combination thereof.
- the Human adenovirus B may be, e.g., a Human adenovirus B serotype 3, Human adenovirus B serotype 7, Human adenovirus B serotype 11 , or any combination thereof.
- the Human adenovirus D may be, e.g., a Human adenovirus D serotype 8, Human adenovirus D serotype 13, Human adenovirus D serotype 19, Human adenovirus D serotype 37, or any combination thereof.
- the Human adenovirus E may be, e.g., a Human adenovirus E serotype 4.
- a method or use disclosed herein reduces or suppresses a level of virus or viral titer in an individual by, e.g., at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90% or at least 95%.
- a method or use disclosed herein reduces or suppresses a level of virus or viral titer in an individual in a range from, e.g., about 10% to about 100%, about 20% to about 100%, about 30% to about 100%, about 40% to about 100%, about 50% to about 100%, about 60% to about 100%, about 70% to about 100%, about 80% to about 100%, about 10% to about 90%, about 20% to about 90%, about 30% to about 90%, about 40% to about 90%, about 50% to about 90%, about 60% to about 90%, about 70% to about 90%, about 10% to about 80%, about 20% to about 80%, about 30% to about 80%, about 40% to about 80%, about 50% to about 80%, or about 60% to about 80%, about 10% to about 70%, about 20% to about 70%, about 30% to about 70%, about 40% to about 70%, or about 50% to about 70%.
- the present specification discloses a method or use of reducing or suppressing viral replication in an individual in need thereof by administering to the individual a Ranpirnase and/or Amphinase disclosed herein or a pharmaceutical composition disclosed herein, wherein administration reduces or suppresses viral replication.
- a virus whose viral replication is reduced or suppressed is a Human adenovirus B, a Human adenovirus D, Human adenovirus E, or any combination thereof.
- the Human adenovirus B may be, e.g., a Human adenovirus B serotype 3, Human adenovirus B serotype 7, Human adenovirus B serotype 1 1 , or any combination thereof.
- the Human adenovirus D may be, e.g., a Human adenovirus D serotype 8, Human adenovirus D serotype 13, Human adenovirus D serotype 19, Human adenovirus D serotype 37, or any combination thereof.
- the Human adenovirus E may be, e.g., a Human adenovirus E serotype 4.
- a method or use disclosed herein reduces or suppresses viral replication in an individual by, e.g., at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90% or at least 95%.
- a method or use disclosed herein reduces or suppresses viral replication in an individual in a range from, e.g., about 10% to about 100%, about 20% to about 100%, about 30% to about 100%, about 40% to about 100%, about 50% to about 100%, about 60% to about 100%, about 70% to about 100%, about 80% to about 100%, about 10% to about 90%, about 20% to about 90%, about 30% to about 90%, about 40% to about 90%, about 50% to about 90%, about 60% to about 90%, about 70% to about 90%, about 10% to about 80%, about 20% to about 80%, about 30% to about 80%, about 40% to about 80%, about 50% to about 80%, or about 60% to about 80%, about 10% to about 70%, about 20% to about 70%, about 30% to about 70%, about 40% to about 70%, or about 50% to about 70%.
- the present specification discloses a method or use of reducing or suppressing protein synthesis in one or more cells of an individual in need thereof by administering to the individual a Ranpirnase and/or Amphinase disclosed herein or a pharmaceutical composition disclosed herein, wherein administration reduces or suppresses protein synthesis in one or more cells.
- a method or use disclosed herein reduces or suppresses protein synthesis in one or more cells of an individual by, e.g., at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90% or at least 95%.
- a method or use disclosed herein reduces or suppresses protein synthesis in one or more cells of an individual in a range from, e.g., about 10% to about 100%, about 20% to about 100%, about 30% to about 100%, about 40% to about 100%, about 50% to about 100%, about 60% to about 100%, about 70% to about 100%, about 80% to about 100%, about 10% to about 90%, about 20% to about 90%, about 30% to about 90%, about 40% to about 90%, about 50% to about 90%, about 60% to about 90%, about 70% to about 90%, about 10% to about 80%, about 20% to about 80%, about 30% to about 80%, about 40% to about 80%, about 50% to about 80%, or about 60% to about 80%, about 10% to about 70%, about 20% to about 70%, about 30% to about 70%, about 40% to about 70%, or about 50% to about 70%.
- the present specification discloses a method or use of reducing or suppressing level of tRNA in one or more cells of an individual in need thereof by administering to the individual a Ranpirnase and/or Amphinase disclosed herein or a pharmaceutical composition disclosed herein, wherein administration reduces or suppresses level of tRNA in one or more cells of an individual.
- a method or use disclosed herein reduces or suppresses a level of tRNA in one or more cells of an individual by, e.g., at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90% or at least 95%.
- a method or use disclosed herein reduces or suppresses a level of tRNA in one or more cells of an individual in a range from, e.g., about 10% to about 100%, about 20% to about 100%, about 30% to about 100%, about 40% to about 100%, about 50% to about 100%, about 60% to about 100%, about 70% to about 100%, about 80% to about 100%, about 10% to about 90%, about 20% to about 90%, about 30% to about 90%, about 40% to about 90%, about 50% to about 90%, about 60% to about 90%, about 70% to about 90%, about 10% to about 80%, about 20% to about 80%, about 30% to about 80%, about 40% to about 80%, about 50% to about 80%, or about 60% to about 80%, about 10% to about 70%, about 20% to about 70%, about 30% to about 70%, about 40% to about 70%, or about 50% to about 70%.
- the present specification discloses a method or use of reducing or suppressing a level of an inflammation inducing molecule in an individual in need thereof by administering to the individual a Ranpirnase and/or Amphinase disclosed herein or a pharmaceutical composition disclosed herein, wherein administration reduces or suppresses a level of an inflammation inducing molecule.
- an inflammation inducing molecule disclosed herein is a substance P (SP), a calcitonin gene-related peptide (CGRP), a glutamate, or a combination thereof.
- a method or use disclosed herein reduces or suppresses a level of an inflammation inducing molecule in an individual by, e.g.
- a method or use disclosed herein reduces or suppresses a level of an inflammation inducing molecule in an individual in a range from, e.g., about 10% to about 100%, about 20% to about 100%, about 30% to about 100%, about 40% to about 100%, about 50% to about 100%, about 60% to about 100%, about 70% to about 100%, about 80% to about 100%, about 10% to about 90%, about 20% to about 90%, about 30% to about 90%, about 40% to about 90%, about 50% to about 90%, about 60% to about 90%, about 70% to about 90%, about 10% to about 80%, about 20% to about 80%, about 30% to about 80%, about 40% to about 80%, about 50% to about 80%, or about 60% to about 80%, about 10% to about 70%, about 20% to about 70%, about 30% to about 70%, about 40% to about 70%, or about 50% to about 70%.
- the present specification discloses a method or use of reducing or suppressing a level of an inflammation inducing prostaglandin in an individual in need thereof by administering to the individual a Ranpirnase and/or Amphinase disclosed herein or a pharmaceutical composition disclosed herein, wherein administration reduces or suppresses a level of an inflammation inducing prostaglandin.
- an inflammation inducing prostaglandin disclosed herein is a 15dPGJ2.
- a method or use disclosed herein reduces or suppresses a level of an inflammation inducing prostaglandin in an individual by, e.g., at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90% or at least 95%.
- a method or use disclosed herein reduces or suppresses a level of an inflammation inducing prostaglandin in an individual in a range from, e.g., about 10% to about 100%, about 20% to about 100%, about 30% to about 100%, about 40% to about 100%, about 50% to about 100%, about 60% to about 100%, about 70% to about 100%, about 80% to about 100%, about 10% to about 90%, about 20% to about 90%, about 30% to about 90%, about 40% to about 90%, about 50% to about 90%, about 60% to about 90%, about 70% to about 90%, about 10% to about 80%, about 20% to about 80%, about 30% to about 80%, about 40% to about 80%, about 50% to about 80%, or about 60% to about 80%, about 10% to about 70%, about 20% to about 70%, about 30% to about 70%, about 40% to about 70%, or about 50% to about 70%.
- the present specification discloses a method or use of stimulating or enhancing a peroxisome proliferator-activated receptor (PPAR) signaling pathway activity in an individual in need thereof by administering to the individual a Ranpirnase and/or Amphinase disclosed herein or a pharmaceutical composition disclosed herein, wherein administration stimulates or enhances a PPAR pathway signal.
- a PPAR signaling pathway activity disclosed herein is a PPAR-a signaling pathway activity, PPAR- ⁇ signaling pathway activity, PPAR- ⁇ (also known as PPAR- ⁇ ) signaling pathway activity, or any combination thereof.
- a method or use disclosed herein stimulates or enhances a PPAR signaling pathway activity in an individual by, e.g., at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90% or at least 95%.
- a method or use disclosed herein stimulates or enhances a PPAR signaling pathway activity in an individual in a range from, e.g., about 10% to about 100%, about 20% to about 100%, about 30% to about 100%, about 40% to about 100%, about 50% to about 100%, about 60% to about 100%, about 70% to about 100%, about 80% to about 100%, about 10% to about 90%, about 20% to about 90%, about 30% to about 90%, about 40% to about 90%, about 50% to about 90%, about 60% to about 90%, about 70% to about 90%, about 10% to about 80%, about 20% to about 80%, about 30% to about 80%, about 40% to about 80%, about 50% to about 80%, or about 60% to about 80%, about 10% to about 70%, about 20% to about 70%, about 30% to about 70%, about 40% to about 70%, or about 50% to about 70%.
- the present specification discloses a method or use of promoting the resolving phenotypic change of M1 to M2 in an individual in need thereof by administering to the individual a Ranpirnase and/or Amphinase disclosed herein or a pharmaceutical composition disclosed herein, wherein administration induces apoptosis of Macrophage M1 cells, promotes differentiation of Macrophage M2 cells or both, thereby promoting the resolving phenotypic change of M1 to M2.
- the present specification discloses a method or use of modulating a level of a Th1 cytokine and/or a level of a Th2 cytokine in an individual in need thereof by administering to the individual a Ranpirnase and/or Amphinase disclosed herein or a pharmaceutical composition disclosed herein, wherein administration reduces or suppresses a level of Interferon-gamma (IFNy), Tumor necrosis factor-alpha (TNF-a), lnterleukin-1 b (IL- 1 b), lnterleukin-12 (IL-12), or a combination thereof released from a Th1 cell, increases or enhances a level of IL-10 released from a Th2 cell, or both, thereby modulating a level of a Th1 cytokine and/or Th2 cytokine.
- IFNy Interferon-gamma
- TNF-a Tumor necrosis factor-alpha
- IL- 1 b lnterleukin-1
- a method or use disclosed herein reduces or suppresses a level of Interferon-gamma (IFNy), Tumor necrosis factor-alpha (TNF-a), lnterleukin-1 b (IL-1 b), lnterleukin-12 (IL- 12), or a combination thereof released from a Th1 cell, or increases or enhances a level of IL-10 released from a Th2 cell, or both in an individual by, e.g., at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90% or at least 95%.
- IFNy Interferon-gamma
- TNF-a Tumor necrosis factor-alpha
- IL-1 b lnterleukin-1 b
- IL-12 lnterle
- a method or use disclosed herein reduces or suppresses a level of Interferon-gamma (IFNy), Tumor necrosis factor-alpha (TNF-a), lnterleukin-1 b (IL-1 b), lnterleukin-12 (IL-12), or a combination thereof released from a Th1 cell, or increases or enhances a level of IL-10 released from a Th2 cell, or both in an individual in a range from, e.g., about 10% to about 100%, about 20% to about 100%, about 30% to about 100%, about 40% to about 100%, about 50% to about 100%, about 60% to about 100%, about 70% to about 100%, about 80% to about 100%, about 10% to about 90%, about 20% to about 90%, about 30% to about 90%, about 40% to about 90%, about 50% to about 90%, about 60% to about 90%, about 70% to about 90%, about 10% to about 80%, about 20% to about 80%, about 30% to about 80%, about 40% to about 80%, about 50% to about about 80%, about 20% to about
- the present specification discloses a method or use of reducing or suppressing a NFKB signaling pathway activity in an individual in need thereof by administering to the individual a Ranpirnase and/or Amphinase disclosed herein or a pharmaceutical composition disclosed herein, wherein administration reduces or suppresses the NFKB signaling pathway activity.
- a method or use disclosed herein stimulates or enhances a NFKB signaling pathway activity in an individual by, e.g., at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90% or at least 95%.
- a method or use disclosed herein stimulates or enhances a NFKB signaling pathway activity in an individual in a range from, e.g., about 10% to about 100%, about 20% to about 100%, about 30% to about 100%, about 40% to about 100%, about 50% to about 100%, about 60% to about 100%, about 70% to about 100%, about 80% to about 100%, about 10% to about 90%, about 20% to about 90%, about 30% to about 90%, about 40% to about 90%, about 50% to about 90%, about 60% to about 90%, about 70% to about 90%, about 10% to about 80%, about 20% to about 80%, about 30% to about 80%, about 40% to about 80%, about 50% to about 80%, or about 60% to about 80%, about 10% to about 70%, about 20% to about 70%, about 30% to about 70%, about 40% to about 70%, or about 50% to about 70%.
- aspects of the present invention provide, in part, administering a Ranpirnase and/or Amphinase disclosed herein or a pharmaceutical composition disclosed herein.
- administering refers to any delivery mechanism that provides a Ranpirnase and/or Amphinase disclosed herein or a pharmaceutical composition disclosed herein to an individual that potentially results in a clinically, therapeutically, or experimentally beneficial result.
- the actual delivery mechanism used to administer a composition disclosed herein to an individual can be determined by a person of ordinary skill in the art by taking into account factors, including, without limitation, the type of viral conjunctivitis, the location of the viral conjunctivitis, the cause of the viral conjunctivitis, the severity of the viral conjunctivitis, the degree of relief desired for viral conjunctivitis, the duration of relief desired for viral conjunctivitis, the level of virus, viral titer, viral replication, protein synthesis, or tRNA desired to be reduced or suppressed, the particular signally pathway, inflammatory molecule, prostaglandin, and/or cytokine being modulated, the particular viral pathogen, Ranpirnase and/or Amphinase, and/or pharmaceutical composition used, the rate of excretion of the particular Ranpirnase and/or Amphinase used, the pharmacodynamics of the particular Ranpirnase and/or Amphinase used, the nature of
- administering an individual a Ranpirnase and/or Amphinase disclosed herein or a pharmaceutical composition disclosed herein includes administering to a surface of a conjunctiva of an individual, administering to a surface of an eye of an individual, or administering to a surface of a conjunctiva and/or an eye of an individual.
- administering an individual a Ranpirnase and/or Amphinase disclosed herein or a pharmaceutical composition disclosed herein includes administering an implant to a conjunctiva of an individual, administering an implant to an eye of an individual, or administering an implant to a conjunctiva and/or an eye of an individual.
- a Ranpirnase and/or Amphinase disclosed herein or a pharmaceutical composition disclosed herein can be administered to an individual using a cellular uptake approach.
- Administration of a composition disclosed herein using a cellular uptake approach comprise a variety of enteral or parenteral approaches including, without limitation, ophthalmic administration, oral administration in any acceptable form, such as, e.g., tablet, liquid, capsule, powder, or the like; topical administration in any acceptable form, such as, e.g., drops, spray, creams, gels or ointments; intravascular administration in any acceptable form, such as, e.g., intravenous injection, intravenous infusion, intra-arterial injection, intra-arterial infusion and catheter instillation into the vasculature; peri- and intra-tissue administration in any acceptable form, such as, e.g., intraperitoneal injection, intramuscular injection, subcutaneous injection, subcutaneous infusion, intraocular injection, retinal injection, or sub-
- biodegradable polymers and methods of use are described in, e.g., Handbook of Biodegradable Polymers (Abraham J. Domb et al., eds., Overseas Publishers Association, 1997).
- a Ranpirnase and/or Amphinase disclosed herein or a pharmaceutical composition disclosed herein is typically administered using an ophthalmic formulation and an ophthalmic route of delivery.
- a Ranpirnase and/or Amphinase disclosed herein or a pharmaceutical composition disclosed herein can be formulated as a topical formulation, such as, e.g., an eye drop, a punctal plug, a salve, an ointment, a lotion, as an enteral formulation, such as, e.g., a tablet, capsule, syrup, or as a parenteral formulation, such as, e.g., an injectable or an intraocular plug.
- Such formulations can be administered, e.g., ophthalmically via ocular instillation, ocular irrigation or topical implant (punctal plug) or parenterally via intraocular injection or implant, intravitreal injection, intracorneal injection or implant or subconjunctival injection or implant.
- a Ranpirnase and/or Amphinase disclosed herein or a pharmaceutical composition disclosed herein is administered in an amount sufficient to treat a viral conjunctivitis, an epidemic keratoconjunctivitis, and/or a pharyngoconjunctival fever, reduce a level of an inflammation inducing molecule and/or an inflammation inducing prostaglandin, stimulate or enhance a peroxisome proliferator-activated receptor (PPAR) pathway signal, promote the resolving phenotypic change of M1 to M2, modulate Th1 and Th2 cytokines, and/or reduce or suppress a NFKB pathway signal.
- PPAR peroxisome proliferator-activated receptor
- the amount of a Ranpirnase and/or Amphinase disclosed herein or a pharmaceutical composition disclosed herein administered is an amount sufficient to reduce one or more physiological conditions or symptom associated with a viral conjunctivitis, an epidemic keratoconjunctivitis, and/or a pharyngoconjunctival fever, reduce a level of an inflammation inducing molecule and/or an inflammation inducing prostaglandin, stimulate or enhance a peroxisome proliferator-activated receptor (PPAR) pathway signal, promote the resolving phenotypic change of M1 to M2, modulate Th1 and Th2 cytokines, and/or reduce or suppress a NFKB pathway signal.
- PPAR peroxisome proliferator-activated receptor
- the term “amount sufficient” includes “effective amount”, “effective dose”, “therapeutically effective amount” or “therapeutically effective dose” and refers to the minimum amount of a Ranpirnase and/or Amphinase disclosed herein or a pharmaceutical composition disclosed herein necessary to achieve the desired therapeutic effect and includes an amount sufficient to reduce one or more physiological conditions or symptom associated with a viral conjunctivitis, an epidemic keratoconjunctivitis, and/or a pharyngoconjunctival fever, an amount sufficient to reduce a level of an inflammation inducing molecule and/or an inflammation inducing prostaglandin, an amount sufficient to stimulate or enhance a peroxisome proliferator-activated receptor (PPAR) pathway signal, an amount sufficient to promote the resolving phenotypic change of M1 to M2, an amount sufficient to modulate Th1 and Th2 cytokines, and/or an amount sufficient to reduce or suppress a NFKB pathway signal.
- PPAR peroxisome proliferator-activ
- an effective amount of a Ranpirnase and/or Amphinase disclosed herein or a pharmaceutical composition disclosed herein modulates one or more physiological conditions or symptoms associated with treating a viral conjunctivitis, an epidemic keratoconjunctivitis, and/or a pharyngoconjunctival fever, reducing a level of an inflammation inducing molecule and/or an inflammation inducing prostaglandin, stimulating or enhancing a peroxisome proliferator-activated receptor (PPAR) pathway signal, promoting the resolving phenotypic change of M1 to M2, modulate Th1 and Th2 cytokines, and/or reducing or suppressing a NFKB pathway signal by, e.g., at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90% or at least 100%.
- PPAR peroxisome proliferator-activated receptor
- an effective amount of a Ranpirnase and/or Amphinase disclosed herein or a pharmaceutical composition disclosed herein modulates one or more physiological conditions or symptom associated with treating a viral conjunctivitis, an epidemic keratoconjunctivitis, and/or a pharyngoconjunctival fever, reducing a level of an inflammation inducing molecule and/or an inflammation inducing prostaglandin, stimulating or enhancing a peroxisome proliferator-activated receptor (PPAR) pathway signal, promoting the resolving phenotypic change of M1 to M2, modulate Th1 and Th2 cytokines, and/or reducing or suppressing a NFKB pathway signal by, e.g., at most 10%, at most 20%, at most 30%, at most 40%, at most 50%, at most 60%, at most 70%, at most 80%, at most 90% or at most 100%.
- PPAR peroxisome proliferator-activated receptor
- an effective amount of a Ranpirnase and/or Amphinase disclosed herein or a pharmaceutical composition disclosed herein modulates one or more physiological conditions or symptom associated with treating a viral conjunctivitis, an epidemic keratoconjunctivitis, and/or a pharyngoconjunctival fever, reducing a level of an inflammation inducing molecule and/or an inflammation inducing prostaglandin, stimulating or enhancing a peroxisome proliferator-activated receptor (PPAR) pathway signal, promoting the resolving phenotypic change of M1 to M2, modulate Th1 and Th2 cytokines, and/or reducing or suppressing a NFKB pathway signal by, e.g., about 10% to about 100%, about 10% to about 90%, about 10% to about 80%, about 10% to about 70%, about 10% to about 60%, about 10% to about 50%, about 10% to about 40%, about 20% to about 100%, about 20% to about 90%, about 20% to about
- an effective amount of a Ranpirnase and/or Amphinase disclosed herein or a pharmaceutical composition disclosed herein modulates one or more physiological conditions or symptom associated with treating a viral conjunctivitis, an epidemic keratoconjunctivitis, and/or a pharyngoconjunctival fever, reducing a level of an inflammation inducing molecule and/or an inflammation inducing prostaglandin, stimulating or enhancing a peroxisome proliferator-activated receptor (PPAR) pathway signal, promoting the resolving phenotypic change of M1 to M2, modulate Th1 and Th2 cytokines, and/or reducing or suppressing a NFKB pathway signal for, e.g., at least one week, at least two weeks, at least three weeks, at least one month, at least two months, at least three months, at least four months, at least five months, at least six months, at least seven months, at least eight months, at least nine months
- the actual effective amount of a Ranpirnase and/or Amphinase disclosed herein or a pharmaceutical composition disclosed herein to be administered to an individual can be determined by a person of ordinary skill in the art by taking into account factors, including, without limitation, the type of viral conjunctivitis, the location of the viral conjunctivitis, the cause of the viral conjunctivitis, the severity of the viral conjunctivitis, the degree of relief desired for viral conjunctivitis, the duration of relief desired for viral conjunctivitis, the level of virus, viral titer, viral replication, protein synthesis, or tRNA desired to be reduced or suppressed, the particular signally pathway, inflammatory molecule, prostaglandin, and/or cytokine being modulated, the particular viral pathogen, Ranpirnase and/or Amphinase, and/or pharmaceutical composition used, the rate of excretion of the particular Ranpirnase and/or Amphinase used, the pharma
- the actual therapeutically effective amount will further depend upon factors, including, without limitation, the frequency of administration, the half-life of a Ranpirnase and/or Amphinase or a pharmaceutical composition, or any combination thereof. It is known by a person of ordinary skill in the art that an effective amount of a Ranpirnase and/or Amphinase disclosed herein or a pharmaceutical composition disclosed herein can be extrapolated from in vitro assays and in vivo administration studies using animal models prior to administration to humans. Wide variations in the necessary effective amount are to be expected in view of the differing efficiencies of the various routes of administration.
- ophthalmic administration generally would be expected to require higher dosage levels than by oral administration
- oral administration generally would be expected to require higher dosage levels than administration by intravenous or intravitreal injection.
- Variations in these dosage levels can be adjusted using standard empirical routines of optimization, which are well-known to a person of ordinary skill in the art.
- the precise therapeutically effective dosage levels and patterns are preferably determined by the attending physician in consideration of the above-identified factors.
- an effective amount of a Ranpirnase and/or Amphinase disclosed herein generally is in the range of about 0. 001 mg/kg/day to about 100 mg/kg/day.
- an effective amount of a Ranpirnase and/or Amphinase disclosed herein may be, e.g., at least 0.001 mg/kg/day, at least 0.01 mg/kg/day, at least 0.1 mg/kg/day, at least 1 .0 mg/kg/day, at least 5.0 mg/kg/day, at least 10 mg/kg/day, at least 15 mg/kg/day, at least 20 mg/kg/day, at least 25 mg/kg/day, at least 30 mg/kg/day, at least 35 mg/kg/day, at least 40 mg/kg/day, at least 45 mg/kg/day, or at least 50 mg/kg/day.
- an effective amount of a Ranpirnase and/or Amphinase disclosed herein may be in the range of, e.g., about 0.001 mg/kg/day to about 10 mg/kg/day, about 0.001 mg/kg/day to about 15 mg/kg/day, about 0.001 mg/kg/day to about 20 mg/kg/day, about 0.001 mg/kg/day to about 25 mg/kg/day, about 0.001 mg/kg/day to about 30 mg/kg/day, about 0.001 mg/kg/day to about 35 mg/kg/day, about 0.001 mg/kg/day to about 40 mg/kg/day, about 0.001 mg/kg/day to about 45 mg/kg/day, about 0.001 mg/kg/day to about 50 mg/kg/day, about 0.001 mg/kg/day to about 75 mg/kg/day, or about 0.001 mg/kg/day to about 100 mg/kg/day.
- an effective amount of a Ranpirnase and/or Amphinase disclosed herein may be in the range of, e.g., about 0.01 mg/kg/day to about 10 mg/kg/day, about 0.01 mg/kg/day to about 15 mg/kg/day, about 0.01 mg/kg/day to about 20 mg/kg/day, about 0.01 mg/kg/day to about 25 mg/kg/day, about 0.01 mg/kg/day to about 30 mg/kg/day, about 0.01 mg/kg/day to about 35 mg/kg/day, about 0.01 mg/kg/day to about 40 mg/kg/day, about 0.01 mg/kg/day to about 45 mg/kg/day, about 0.01 mg/kg/day to about 50 mg/kg/day, about 0.01 mg/kg/day to about 75 mg/kg/day, or about 0.01 mg/kg/day to about 100 mg/kg/day.
- an effective amount of a Ranpirnase and/or Amphinase disclosed herein may be in the range of, e.g., about 0.1 mg/kg/day to about 10 mg/kg/day, about 0.1 mg/kg/day to about 15 mg/kg/day, about 0.1 mg/kg/day to about 20 mg/kg/day, about 0.1 mg/kg/day to about 25 mg/kg/day, about 0.1 mg/kg/day to about 30 mg/kg/day, about 0.1 mg/kg/day to about 35 mg/kg/day, about 0.1 mg/kg/day to about 40 mg/kg/day, about 0.1 mg/kg/day to about 45 mg/kg/day, about 0.1 mg/kg/day to about 50 mg/kg/day, about 0.1 mg/kg/day to about 75 mg/kg/day, or about 0.1 mg/kg/day to about 100 mg/kg/day.
- an effective amount of a Ranpirnase and/or Amphinase disclosed herein may be in the range of, e.g., about 1 mg/kg/day to about 10 mg/kg/day, about 1 mg/kg/day to about 15 mg/kg/day, about 1 mg/kg/day to about 20 mg/kg/day, about 1 mg/kg/day to about 25 mg/kg/day, about 1 mg/kg/day to about 30 mg/kg/day, about 1 mg/kg/day to about 35 mg/kg/day, about 1 mg/kg/day to about 40 mg/kg/day, about 1 mg/kg/day to about 45 mg/kg/day, about 1 mg/kg/day to about 50 mg/kg/day, about 1 mg/kg/day to about 75 mg/kg/day, or about 1 mg/kg/day to about 100 mg/kg/day.
- an effective amount of a Ranpirnase and/or Amphinase disclosed herein may be in the range of, e.g. , about 5 mg/kg/day to about 10 mg/kg/day, about 5 mg/kg/day to about 15 mg/kg/day, about 5 mg/kg/day to about 20 mg/kg/day, about 5 mg/kg/day to about 25 mg/kg/day, about 5 mg/kg/day to about 30 mg/kg/day, about 5 mg/kg/day to about 35 mg/kg/day, about 5 mg/kg/day to about 40 mg/kg/day, about 5 mg/kg/day to about 45 mg/kg/day, about 5 mg/kg/day to about 50 mg/kg/day, about 5 mg/kg/day to about 75 mg/kg/day, or about 5 mg/kg/day to about 100 mg/kg/day.
- an effective amount of a Ranpirnase and/or Amphinase disclosed herein generally is in the range of about 0. 001 mg/day to about 100 mg/day.
- an effective amount of a Ranpirnase and/or Amphinase disclosed herein may be, e.g., at least 0.001 mg/day, at least 0.01 mg/day, at least 0.1 mg/day, at least 1.0 mg/day, at least 5.0 mg/day, at least 10 mg/day, at least 15 mg/day, at least 20 mg/day, at least 25 mg/day, at least 30 mg/day, at least 35 mg/day, at least 40 mg/day, at least 45 mg/day, or at least 50 mg/day.
- an effective amount of a Ranpirnase and/or Amphinase disclosed herein may be in the range of, e.g., about 0.001 mg/day to about 10 mg/day, about 0.001 mg/day to about 15 mg/day, about 0.001 mg/day to about 20 mg/day, about 0.001 mg/day to about 25 mg/day, about 0.001 mg/day to about 30 mg/day, about 0.001 mg/day to about 35 mg/day, about 0.001 mg/day to about 40 mg/day, about 0.001 mg/day to about 45 mg/day, about 0.001 mg/day to about 50 mg/day, about 0.001 mg/day to about 75 mg/day, or about 0.001 mg/day to about 100 mg/day.
- an effective amount of a Ranpirnase and/or Amphinase disclosed herein may be in the range of, e.g., about 0.01 mg/day to about 10 mg/day, about 0.01 mg/day to about 15 mg/day, about 0.01 mg/day to about 20 mg/day, about 0.01 mg/day to about 25 mg/day, about 0.01 mg/day to about 30 mg/day, about 0.01 mg/day to about 35 mg/day, about 0.01 mg/day to about 40 mg/day, about 0.01 mg/day to about 45 mg/day, about 0.01 mg/day to about 50 mg/day, about 0.01 mg/day to about 75 mg/day, or about 0.01 mg/day to about 100 mg/day.
- an effective amount of a Ranpirnase and/or Amphinase disclosed herein may be in the range of, e.g. , about 0.1 mg/day to about 10 mg/day, about 0.1 mg/day to about 15 mg/day, about 0.1 mg/day to about 20 mg/day, about 0.1 mg/day to about 25 mg/day, about 0.1 mg/day to about 30 mg/day, about 0.1 mg/day to about 35 mg/day, about 0.1 mg/day to about 40 mg/day, about 0.1 mg/day to about 45 mg/day, about 0.1 mg/day to about 50 mg/day, about 0.1 mg/day to about 75 mg/day, or about 0.1 mg/day to about 100 mg/day.
- an effective amount of a Ranpirnase and/or Amphinase disclosed herein may be in the range of, e.g., about 1 mg/day to about 10 mg/day, about 1 mg/day to about 15 mg/day, about 1 mg/day to about 20 mg/day, about 1 mg/day to about 25 mg/day, about 1 mg/day to about 30 mg/day, about 1 mg/day to about 35 mg/day, about 1 mg/day to about 40 mg/day, about 1 mg/day to about 45 mg/day, about 1 mg/day to about 50 mg/day, about 1 mg/day to about 75 mg/day, or about 1 mg/day to about 100 mg/day.
- an effective amount of a Ranpirnase and/or Amphinase disclosed herein may be in the range of, e.g., about 5 mg/day to about 10 mg/day, about 5 mg/day to about 15 mg/day, about 5 mg/day to about 20 mg/day, about 5 mg/day to about 25 mg/day, about 5 mg/day to about 30 mg/day, about 5 mg/day to about 35 mg/day, about 5 mg/day to about 40 mg/day, about 5 mg/day to about 45 mg/day, about 5 mg/day to about 50 mg/day, about 5 mg/day to about 75 mg/day, or about 5 mg/day to about 100 mg/day.
- PPAR peroxisome proliferator-activated receptor
- an effective amount of a Ranpirnase and/or Amphinase disclosed herein or a pharmaceutical composition disclosed herein can be administered once to an individual, e.g. , as a single application.
- treatment of a viral conjunctivitis, an epidemic keratoconjunctivitis, and/or a pharyngoconjunctival fever, reduction or suppression of a level of an inflammation inducing molecule and/or an inflammation inducing prostaglandin, stimulation or enhancement of a peroxisome proliferator-activated receptor (PPAR) pathway signal, promotion of the resolving phenotypic change of M1 to M2, modulation of Th1 and Th2 cytokines, and/or reduction or suppression of a NFKB pathway signal may comprise multiple administrations of an effective amount of a Ranpirnase and/or Amphinase disclosed herein or a pharmaceutical composition disclosed herein carried out over a range of time periods, such as, e
- PPAR peroxisome
- a Ranpirnase and/or Amphinase disclosed herein or a pharmaceutical composition disclosed herein can be administered one, two, three, four, five or six times daily to an individual.
- the timing of administration can vary from individual to individual, depending upon such factors as the severity of an individual's symptoms.
- an effective amount of a Ranpirnase and/or Amphinase disclosed herein or a pharmaceutical composition disclosed herein can be administered to an individual three to six time daily for an indefinite period of time, or until the individual no longer requires therapy.
- a method or use of treating a viral conjunctivitis disclosed herein substantially affects virally-infected cells.
- a method or use of treating a viral conjunctivitis affects, e.g., at least 75%, at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91 %, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99%, of virally-infected cells.
- a method or use of treating a viral conjunctivitis affects, e.g., at most 75%, at most 80%, at least 85%, at most 86%, at most 87%, at least 88%, at most 89%, at most 90%, at most 91 %, at most 92%, at most 93%, at most 94%, at most 95%, at most 96%, at most 97%, at most 98%, or at most 99%, of virally-infected cells.
- a method or use of treating a viral conjunctivitis affects, e.g., about 75% to about 100%, about 80% to about 100%, about 85% to about 100%, about 90% to about 100%, about 95% to about 100%, about 75% to about 99%, about 80% to about 99%, about 85% to about 99%, about 90% to about 99%, about 95% to about 99%, about 75% to about 97%, about 80% to about 97%, about 85% to about 97%, about 90% to about 97%, or about 95% to about 97%, of virally-infected cells.
- a method or use of treating a viral conjunctivitis disclosed herein does not substantially affect nonvirally-infected cells.
- a method or use of treating a viral conjunctivitis does not affect, e.g., at least 75%, at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91 %, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99%, of nonvirally-infected cells.
- a method or use of treating a viral conjunctivitis does not affect, e.g., at most 75%, at most 80%, at least 85%, at most 86%, at most 87%, at least 88%, at most 89%, at most 90%, at most 91 %, at most 92%, at most 93%, at most 94%, at most 95%, at most 96%, at most 97%, at most 98%, or at most 99%, of nonvirally-infected cells.
- a method or use of treating a viral conjunctivitis does not affect, e.g., about 75% to about 100%, about 80% to about 100%, about 85% to about 100%, about 90% to about 100%, about 95% to about 100%, about 75% to about 99%, about 80% to about 99%, about 85% to about 99%, about 90% to about 99%, about 95% to about 99%, about 75% to about 97%, about 80% to about 97%, about 85% to about 97%, about 90% to about 97%, or about 95% to about 97%, of nonvirally-infected cells.
- a Ranpirnase and/or Amphinase disclosed herein or a pharmaceutical composition disclosed herein can also be administered to an individual in combination with other therapeutic compounds to increase the overall therapeutic effect of the treatment.
- the use of multiple compounds to treat an indication can increase the beneficial effects while reducing the presence of side effects.
- a Ranpirnase and/or Amphinase disclosed herein can either be co-formulated with or administered sequentially with immunomodulatory drugs such as steroids, NSAIDs, cyclosporine A or other therapeutics in order to enhance the immunomodulation achieved using a Ranpirnase and/or Amphinase alone.
- a Ranpirnase and/or Amphinase disclosed herein can either be co-formulated with or administered sequentially with antibiotics currently prescribed for bacterial conjunctivitis.
- a method of treating a viral conjunctivitis in an individual in need thereof comprising administering to a surface of a conjunctiva and/or an eye of the individual a pharmaceutical composition comprising a therapeutic effective amount of one or more Ranpirnases and/or a therapeutic effective amount of one or more Amphinase, wherein administration reduces a symptom associated with the viral conjunctivitis, thereby treating the individual.
- composition comprising one or more Ranpirnases and/or one or more Amphinase for treating of a viral conjunctivitis.
- a method of reducing or suppressing replication of a virus infecting an individual in need thereof comprising administering to a surface of a conjunctiva and/or an eye of the individual a pharmaceutical composition comprising a therapeutic effective amount of one or more Ranpirnases and/or a therapeutic effective amount of one or more Amphinase, wherein administration reduces or suppresses replication of the virus infecting the individual.
- composition comprising one or more Ranpirnases and/or one or more Amphinase for reducing or suppressing replication of a virus infecting an individual.
- a method of reducing or suppressing protein synthesis in one or more cells of an individual in need thereof comprising administering to a surface of a conjunctiva and/or an eye of the individual a pharmaceutical composition comprising a therapeutic effective amount of one or more Ranpirnases and/or a therapeutic effective amount of one or more Amphinase, wherein administration reduces or suppresses protein synthesis in one or more cells of the individual.
- composition comprising one or more Ranpirnases and/or one or more Amphinase for reducing or suppressing protein synthesis in one or more cells of an individual.
- a method of reducing or suppressing a level of tRNA in one or more cells of an individual in need thereof comprising administering to a surface of a conjunctiva and/or an eye of the individual a pharmaceutical composition comprising a therapeutic effective amount of one or more Ranpirnases and/or a therapeutic effective amount of one or more Amphinase, wherein administration reduces or suppresses a level of tRNA in one or more cells of the individual.
- composition comprising one or more Ranpirnases and/or one or more Amphinase for reducing or suppressing a level of tRNA in one or more cells of an individual.
- the Human adenovirus D is a Human adenovirus D serotype 8, a Human adenovirus D serotype 13, a Human adenovirus D serotype 19, a Human adenovirus D serotype 37, or any combination thereof.
- a method of reducing or suppressing a level of an inflammation inducing molecule in an individual in need thereof by administering to a surface of a conjunctiva and/or an eye of the individual a pharmaceutical composition comprising a therapeutic effective amount of one or more Ranpirnases and/or a therapeutic effective amount of one or more Amphinase, wherein administration reduces or suppresses the level of the inflammation inducing molecule in the individual.
- composition comprising one or more Ranpirnases and/or one or more Amphinase for reducing or suppressing a level of an inflammation inducing molecule.
- the inflammation inducing molecule is a substance P, a calcitonin gene-related peptide, a glutamate, or a combination thereof.
- composition comprising one or more Ranpirnases and/or one or more Amphinase for reducing or suppressing a level of an inflammation inducing prostaglandin.
- a method of stimulating or enhancing a peroxisome proliferator-activated receptor (PPAR) signaling pathway activity in an individual in need thereof by administering to a surface of a conjunctiva and/or an eye of the individual a pharmaceutical composition comprising a therapeutic effective amount of one or more Ranpirnases and/or a therapeutic effective amount of one or more Amphinase, wherein administration stimulates or enhances the PPAR signaling pathway activity in the individual.
- PPAR peroxisome proliferator-activated receptor
- a pharmaceutical composition comprising one or more Ranpirnases and/or one or more Amphinase for stimulating or enhancing a peroxisome proliferator-activated receptor (PPAR) pathway signal.
- PPAR signaling pathway activity is a PPAR-a signaling pathway activity, a PPAR- ⁇ signaling pathway activity, a PPAR- ⁇ (also known as PPAR- ⁇ ) signaling pathway activity, or any combination thereof
- a method of promoting the resolving phenotypic change of M1 to M2 in an individual in need thereof by administering to a surface of a conjunctiva and/or an eye of the individual a pharmaceutical composition comprising a therapeutic effective amount of one or more Ranpirnases and/or a therapeutic effective amount of one or more Amphinase, wherein administration induces apoptosis of Macrophage M1 cells, promotes differentiation of Macrophage M2 cells or both, thereby promoting the resolving phenotypic change of M1 to M2 in the individual.
- composition comprising one or more Ranpirnases and/or one or more Amphinase for promoting the resolving phenotypic change of M1 to M2.
- IFNy Interferon- gamma
- TNF-a Tumor necrosis factor-alpha
- a pharmaceutical composition comprising one or more Ranpirnases and/or one or more Amphinase for modulating a level of a Th1 cytokine and/or a level of a Th2 cytokine.
- invention 29 which reduces the levels of Interferon-gamma (IFNy), Tumor necrosis factor-alpha (TNF-a), lnterleukin-1 b (IL-1 b), lnterleukin-12 (IL-12), or a combination thereof released from a Th1 cell, increases the level of IL-10 released from a Th2 cell, or both, thereby modulating Th1 and Th2 cytokines.
- IFNy Interferon-gamma
- TNF-a Tumor necrosis factor-alpha
- IL-1 b lnterleukin-1 b
- IL-12 lnterleukin-12
- a method of reducing or suppressing a NFKB signaling pathway activity in an individual in need thereof by administering to a surface of a conjunctiva and/or an eye of the individual a pharmaceutical composition comprising a therapeutic effective amount of one or more Ranpirnases and/or a therapeutic effective amount of one or more Amphinase, wherein administration reduces or suppresses the NFKB signaling pathway activity in the individual.
- composition comprising one or more Ranpirnases and/or one or more Amphinase for reducing or suppressing a NFKB signaling pathway activity.
- SEQ ID NO: 20 SEQ ID NO: 21 , SEQ ID NO: 22, SEQ ID NO: 23, SEQ ID NO: 24, SEQ ID NO: 25, or SEQ ID NO: 26; or an amino acid sequence having at least 1 , 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 , 12, 13,
- SEQ ID NO: 1 SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 , SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO:
- SEQ ID NO: 21 SEQ ID NO: 22, SEQ ID NO: 23, SEQ ID NO: 24, SEQ ID NO: 25, or SEQ ID NO: 26; or an amino acid sequence having at most 1 , 2, 3, 4, 5, 6, 7, 8, 9, 10, 1 1 , 12, 13, 14, or 15 noncontiguous amino acid deletions, additions, and/or substitutions relative to SEQ ID NO: 1 , SEQ ID NO:
- SEQ ID NO: 2 SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 1 1 , SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 21 , SEQ ID NO: 22, SEQ ID NO: 23, SEQ ID NO: 24, SEQ ID NO: 25, or SEQ ID NO: 26.
- the one or more Amphinase comprise an amino acid sequence having at least 1 , 2, 3, 4, 5, 6, 7, 8, 9, 10, 1 1 , 12, 13, 14, or 15 contiguous amino acid deletions, additions, and/or substitutions relative to SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 29, SEQ ID NO: 30, SEQ ID NO: 31 , SEQ ID NO: 32, SEQ ID NO: 33, SEQ ID NO: 34, SEQ ID NO: 35, SEQ ID NO: 36, SEQ ID NO: 37, SEQ ID NO: 38, or SEQ ID NO: 39; or an amino acid sequence having at most 1 , 2, 3, 4, 5, 6, 7, 8, 9, 10, 1 1 , 12, 13, 14, or 15 contiguous amino acid deletions, additions, and/or substitutions relative to SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 29, SEQ ID NO: 30, SEQ ID NO: 31 , SEQ ID NO: 32, SEQ ID NO: 33, SEQ ID NO: 34,
- SEQ ID NO: 28 SEQ ID NO: 29, SEQ ID NO: 30, SEQ ID NO: 31 , SEQ ID NO: 32, SEQ ID NO: 33, SEQ ID NO: 34, SEQ ID NO: 35, SEQ ID NO: 36, SEQ ID NO: 37, SEQ ID NO: 38, or SEQ ID NO: 39.
- the inflammation inducing molecule is a substance P (SP), calcitonin gene-related peptide (CGRP), glutamate, or a combination thereof.
- administration or use of the one or more Ranpirnase and/or the one or more Amphinase reduces or suppresses the level of the inflammation inducing molecule by at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90% or at least 95%; or reduces or suppresses the level of the inflammation inducing molecule in a range from, e.g., about 10% to about 100%, about 20% to about 100%, about 30% to about 100%, about 40% to about 100%, about 50% to about 100%, about 60% to about 100%, about 70%
- the PPAR signaling pathway activity is a PPAR-a signaling pathway activity, a PPAR- ⁇ signaling pathway activity, a PPAR- ⁇ signaling pathway activity, or a combination thereof.
- the modulation of the level of the Th1 cytokine and/or the Th2 cytokine comprises reducing the level of Interferon-gamma (IFNy), Tumor necrosis factor-alpha (TNF-a), lnterleukin-1 b (IL-1 b), lnterleukin-12 (IL-12), or a combination thereof released from a Th1 cell, increasing the level of IL-10 released from a Th2 cell, or any combination thereof.
- IFNy Interferon-gamma
- TNF-a Tumor necrosis factor-alpha
- IL-1 b lnterleukin-1 b
- IL-12 lnterleukin-12
- administration or use of the one or more Ranpirnase and/or the one or more Amphinase reduces or suppresses a NFKB signaling pathway activity by at least 1 0%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, or at least 90%; or reduces or suppresses a NFKB signaling pathway activity in a range from about 5% to about 1 00%, about 1 0% to about 100%, about 20% to about 1 00%, about 30% to about 1 00%, about 40% to about 1 00%, about 50% to about 100%, about 60% to about 100%, about 70% to about 100%, about 80% to about 1 00%, about 10% to about 90%, about 20% to about 90%, about 30% to about 90%, about 40% to about 90%, about 50% to about 90%, about 60% to about 90%, about 70% to about 90%, about 1 0% to about 80%, about 20% to about 80%, about 30% to about 80%, about 40% to about 90%, about 50% to about 90%, about
- composition further comprises one or more pharmaceutically-acceptable carriers and optionally one or more pharmaceutically-acceptable components.
- ophthalmic formulation is a liquid formulation, a colloidal formulation, a semi-solid formulation or a solid formulation.
- ophthalmic formulation is administered by an ocular instillation, an ocular irrigation, an intraocular injection, an intracorneal injection, intravitreal injection or a subconjunctival injection.
- controlled release delivery platform is an extended release formulation or a sustained release formulation.
- ophthalmic formulation is an ocular implant, an ophthalmic implant, a punctal plug, an intraocular implant, an intracorneal implant or a subconjunctival implant.
- ophthalmic formulation is an ocular implant, an ophthalmic implant, a punctal plug, an intraocular implant, an intracorneal implant or a subconjunctival implant.
- composition comprising one or more Ranpirnases and/or one or more Amphinase as a medicament for the treatment of a viral conjunctivitis.
- a pharmaceutical composition comprising one or more Ranpirnases and/or one or more Amphinase as a medicament for reducing or suppressing replication of a virus infecting an individual.
- composition comprising one or more Ranpirnases and/or one or more Amphinase as a medicament for reducing or suppressing protein synthesis in one or more cells of an individual.
- a pharmaceutical composition comprising one or more Ranpirnases and/or one or more Amphinase as a medicament for reducing or suppressing a level of tRNA in one or more cells of an individual.
- the antiviral activity of Ranpirnase was evaluated using three in vitro assays. In each assay, Human Adenovirus 5 (AD 5 strain NYS #98-1836) or Human Adenovirus 8 (Ad8 strain 13306) was used to infect cells in order to determine whether Ranpirnase could inhibited the cytopathic effects of virus in infected cells and/or could reduce the amount of virus being produced from those infected cells.
- Human Adenovirus 5 AD 5 strain NYS #98-1836
- Human Adenovirus 8 Ad8 strain 13306
- Ranpirnase was serially diluted in the prescribed test medium using eight half-log dilutions. Each dilution was added to 5 wells of a 96-well plate with 80% to 100% confluent cells, and three wells of each dilution were then infected with one of the two test viruses. Two wells remained uninfected as controls for toxicity. Six wells per plate were set aside as uninfected, untreated cell controls, and six wells per plate were infected with no treatment as virus controls. 2', 3'-Dideoxycytidine (ddC), a known active compound, was assayed in parallel as a positive control. Assay plates were incubated at 37°C with 5% CO2.
- ddC 3'-Dideoxycytidine
- CPE reduction assay was performed by scoring each well for cytopathic effect on a scale of 1-4 with a score of 4 meaning that all cells showed CPE.
- CPE reduction assay was completed, a neutral red lysosomal uptake assay was conducted by filling each well with 0.01 1 % (m/v) neutral red, a vital stain. The plates then were incubated for about 2 hours at 37°C in the dark. The unincorporated neutral red solution was removed from the wells and the incorporated dye was then eluted by adding S0rensen's citrate-buffered ethanol. The plates were then read on a spectrophotometer at 540 nm to quantify the neutral red taken up by the healthy cells. The optical density of test wells was converted to percent of cell control and normalized to the virus controls.
- the concentration of test compound required to inhibit CPE by 50% or reduce red uptake into cells by 50% was calculated by regression analysis.
- the toxicity of the compound without virus present was similarly calculated using the uninfected wells treated with test compounds compared with untreated cell controls.
- the concentration of compound that would cause 50% cytotoxic effects in the absence of virus (CC50) was estimated by linear regression analysis.
- the selectivity index (SI) is the CC50 divided by EC50. Assays were repeated using four 10-fold dilutions to verify inactive results.
- the CPE/neutral red assay format was used with 8 half-log dilutions plated in triplicate, followed by the harvest of supernatant fluid from these wells to be assayed for infectious virus using the virus yield reduction assay in triplicate to confirm and quantify the antiviral activity of Ranpirnase.
- the virus yield reduction assay was used to determine actual virus amounts in the presence and absence of the test compound; this is the confirmatory assay for antiviral activity. After a 5-day incubation at 37°C in an incubator infused with 5% CO2 (time when maximum CPE was observed in virus-infected control cells), an aliquot of supernatant fluid was removed from each test well. Replicate wells of each compound concentration or control were pooled and frozen at -80°C. Samples were thawed and diluted by 10-fold serial dilutions. A 100 pL aliquot of each dilution was then plated onto 4 replicate wells of 96-well plates seeded with the applicable cells for each virus strain.
- Adenovirus serotypes include, without limitation, a Human adenovirus B serotype 3 (Ad3), Human adenovirus B serotype 7 (Ad7), Human adenovirus B serotype 1 1 (Ad1 1), a Human adenovirus D serotype 13 (Ad13), a Human adenovirus D serotype 19 (Ad19), a Human adenovirus D serotype 37 (Ad37) or a Human adenovirus E serotype 4 (Ad4).
- viruses include, without limitation, a herpes simplex virus (HSV), a varicella-zoster virus (VZV), a picornavirus (enterovirus 70, coxsackie A24) or a poxvirus (Molluscum contagiosum virus, vaccinia).
- HSV herpes simplex virus
- VZV varicella-zoster virus
- picornavirus enterovirus 70, coxsackie A24
- poxvirus Molluscum contagiosum virus, vaccinia
- 96-well plates were seeded with A549 cells at 1 x 10 5 cells/mL and incubated overnight at 37°C with 5% CO2.
- Ranpirnase was serially diluted to concentrations of 1 .0 ⁇ , 10 ⁇ and 50 ⁇ .
- 100 ⁇ _ of each dilution was added to 3 wells of a 96-well plate with 80% to 100% confluent cells.
- 100 ⁇ _ of a lysis buffer containing 0.25% TRITON X-100 was added to 6 wells (positive cytotoxicity control) and 100 ⁇ _ of tissue culture media with no Ranpirnase was added to 6 wells (negative cytotoxicity control).
- the fluorometric stain acts as a redox indicator that is reduced to a fluorescent form by metabolically active living cells. Fluorescence was then be read with a plate reader (Biotek Synergy 2; Biotek), with a 500/27-nm excitation filter and a 620/40-nm emission filter, at a sensitivity of 35.
- Ranpirnase and saline control rabbits were treated in both eyes eight times daily for 9 days, whereas cidofovir rabbits were treated in both eyes twice daily for 7 days.
- the MMTS score used was as follows: 0.0 - 0.5, Non-Irritating (N); 0.6 - 2.5, Practically Non-Irritating (PN); 2.6 - 15.0, Minimally Irritating (Mi); 15.1 - 25.0, Mildly Irritating (M 2 ); 25.1 - 50.0, Moderately Irritating (M 3 ); 50.1 - 80.0, Severely Irritating (S); 80.1 - 100.0, Extremely Irritating (E); and 100.1 - 1 10.0, Maximally Irritating (Mx).
- the ocular samples were assayed for Ad5 titers by performing a plaque reduction assay. Samples were diluted 1 :10 and these dilutions were inoculated onto duplicate wells of a 24 well multi-plate containing A549 monolayers. The virus was adsorbed for 3 hours at 37°C in a 5% C0 2 -water vapor atmosphere without constant rocking. After adsorption, 1 mL of medium plus 0.5% methylcellulose was added to each well, and the plates were incubated at 37°C in a 5% C0 2 -water vapor atmosphere. After 7 days, the cells were stained with 0.5% gentian violet, and the number of plaques counted using a dissecting microscope (25x).
- the viral titers were then calculated, and will be expressed as plaque-forming units per milliliter (PFU/mL). Data from the study were analyzed using analysis of variance (ANOVA) with Fisher's pair-wise comparisons and X 2 analyses using True Epistat and/or Minitab statistical software. Significance was established at the P ⁇ 0.05 confidence level.
- Adenovirus serotypes include, without limitation, a Human adenovirus B serotype 3 (Ad3), Human adenovirus B serotype 7 (Ad7), Human adenovirus B serotype 1 1 (Ad1 1), a Human adenovirus D serotype 8 (Ad8), a Human adenovirus D serotype 13 (Ad13), a Human adenovirus D serotype 19 (Ad19), a Human adenovirus D serotype 37 (Ad37) or a Human adenovirus E serotype 4 (Ad4).
- Ad3 Human adenovirus B serotype 3
- Ad7 Human adenovirus B serotype 7
- Ad8 Human adenovirus B serotype 1 1
- Ad8 Human adenovirus D serotype 8
- Ad19 Human adenovirus D serotype 19
- Ad19 Human adenovirus D serotype 37
- Ad37 Human a
- viruses include, without limitation, a herpes simplex virus (HSV), a varicella-zoster virus (VZV), a picornavirus (enterovirus 70, coxsackie A24) or a poxvirus (Molluscum contagiosum virus, vaccinia).
- HSV herpes simplex virus
- VZV varicella-zoster virus
- picornavirus enterovirus 70, coxsackie A24
- poxvirus Molluscum contagiosum virus, vaccinia
Abstract
Description
Claims
Priority Applications (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
RU2018109568A RU2733432C1 (en) | 2015-09-25 | 2016-09-25 | Treatment of viral conjunctivitis with application of ranpirnase and/or amphinase |
CN201680064720.1A CN108350458B (en) | 2015-09-25 | 2016-09-25 | Treatment of viral conjunctivitis with ranpirnase and/or amphinase |
MX2018003528A MX2018003528A (en) | 2015-09-25 | 2016-09-25 | Viral conjunctivitis treatment using ranpirnase and/or amphinase. |
AU2016326750A AU2016326750B2 (en) | 2015-09-25 | 2016-09-25 | Viral conjunctivitis treatment using ranpirnase and/or amphinase |
JP2018536072A JP6794454B2 (en) | 2015-09-25 | 2016-09-25 | Treatment of viral conjunctivitis with ranpirnase and / or ampinase |
KR1020187011450A KR20180058791A (en) | 2015-09-25 | 2016-09-25 | Treatment of viral conjunctivitis using lanfunase and / or ampicillin |
EP16849832.7A EP3353304B1 (en) | 2015-09-25 | 2016-09-25 | Viral conjunctivitis treatment using ranpirnase |
CA2999514A CA2999514A1 (en) | 2015-09-25 | 2016-09-25 | Viral conjunctivitis treatment using ranpirnase and/or amphinase |
IL258237A IL258237B (en) | 2015-09-25 | 2018-03-20 | Viral conjunctivitis treatment using ranpirnase and/or amphinase |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562233267P | 2015-09-25 | 2015-09-25 | |
US62/233,267 | 2015-09-25 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2017053923A1 true WO2017053923A1 (en) | 2017-03-30 |
Family
ID=58387443
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2016/053629 WO2017053923A1 (en) | 2015-09-25 | 2016-09-25 | Viral conjunctivitis treatment using ranpirnase and/or amphinase |
Country Status (12)
Country | Link |
---|---|
US (3) | US9682130B2 (en) |
EP (1) | EP3353304B1 (en) |
JP (1) | JP6794454B2 (en) |
KR (1) | KR20180058791A (en) |
CN (1) | CN108350458B (en) |
AU (1) | AU2016326750B2 (en) |
CA (1) | CA2999514A1 (en) |
IL (1) | IL258237B (en) |
MX (1) | MX2018003528A (en) |
RU (1) | RU2733432C1 (en) |
SG (1) | SG10201912974VA (en) |
WO (1) | WO2017053923A1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019222533A1 (en) * | 2018-05-18 | 2019-11-21 | Okogen, Inc. | Methods of treating ocular melanoma |
WO2021216909A1 (en) * | 2020-04-23 | 2021-10-28 | Okogen, Inc. | Treatment of viral conjunctivitis |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110038120B (en) * | 2019-04-02 | 2022-12-23 | 河南师范大学 | Application of rana pipiens anti-tumor enzyme fusion protein as tumor treatment drug |
CN110964798B (en) * | 2020-03-05 | 2023-07-07 | 东北农业大学 | Method for identifying genetic sex of rana chensinensis by using TRAP molecular marker technology |
Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5559212A (en) | 1988-04-06 | 1996-09-24 | Alfacell Corporation | Frog embryo and egg-derived tumor cell anti-proliferation protein |
US5728805A (en) | 1988-04-06 | 1998-03-17 | Alfacell Corp. | Pharmaceuticals and method for making them |
US6175003B1 (en) | 1999-09-10 | 2001-01-16 | Alfacell Corporation | Nucleic acids encoding ribonucleases and methods of making them |
US6239257B1 (en) | 1998-12-30 | 2001-05-29 | Alfacell Corporation | Family of proteins belonging to the pancreatic ribonuclease a superfamily |
US7229824B2 (en) | 2003-07-17 | 2007-06-12 | Alfacell Corporation | Ribonucleases and methods of making them recombinantly |
US20090047665A1 (en) * | 2003-09-11 | 2009-02-19 | Ibis Biosciences, Inc. | Compositions for use in identification of adenoviruses |
US8518399B2 (en) | 2010-11-17 | 2013-08-27 | Tamir Biotechnology, Inc. | Methods of treating infections originating from viruses in the herpesviridae family |
US8663964B2 (en) | 2011-07-20 | 2014-03-04 | Tamir Biotechnology, Inc. | Methods of treating human papillomavirus |
WO2015110429A1 (en) * | 2014-01-22 | 2015-07-30 | Nicox S.A. | Composition effective against viral conjunctivitis |
WO2016205109A1 (en) | 2015-06-15 | 2016-12-22 | Tamir Biotechnology, Inc. | Pharmaceuticals for treatment of viral infections of the eye |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5326347A (en) * | 1991-08-12 | 1994-07-05 | Cumming J Stuart | Intraocular implants |
RU2093165C1 (en) * | 1993-07-06 | 1997-10-20 | Линд Роберт Мейнгардтович | Agent for conjunctivitis treatment |
ES2238702T3 (en) * | 1995-12-21 | 2005-09-01 | Alcon Laboratories, Inc. | USE OF CERTAIN COMPOUNDS OF ISOQUINOLINSULFONILO IN THE TREATMENT OF GLAUCOMAS AND OCULAR ISCHEMIES. |
GB9920674D0 (en) * | 1999-09-01 | 1999-11-03 | Evolutec Limited | Treatment of conjunctivitis |
US9919034B2 (en) * | 2014-03-28 | 2018-03-20 | Tamir Biotechnology, Inc. | Methods of treating and prophylactically protecting mammalian patients infected by viruses classified in Baltimore group V |
EP3122372B1 (en) * | 2014-03-28 | 2018-11-28 | Tamir Biotechnology, Inc. | Onconase for use in treating or preventing viral infections |
-
2016
- 2016-09-25 WO PCT/US2016/053629 patent/WO2017053923A1/en active Application Filing
- 2016-09-25 US US15/275,442 patent/US9682130B2/en active Active
- 2016-09-25 JP JP2018536072A patent/JP6794454B2/en active Active
- 2016-09-25 EP EP16849832.7A patent/EP3353304B1/en active Active
- 2016-09-25 CA CA2999514A patent/CA2999514A1/en active Pending
- 2016-09-25 CN CN201680064720.1A patent/CN108350458B/en active Active
- 2016-09-25 KR KR1020187011450A patent/KR20180058791A/en not_active Application Discontinuation
- 2016-09-25 RU RU2018109568A patent/RU2733432C1/en active
- 2016-09-25 MX MX2018003528A patent/MX2018003528A/en unknown
- 2016-09-25 AU AU2016326750A patent/AU2016326750B2/en active Active
- 2016-09-26 SG SG10201912974VA patent/SG10201912974VA/en unknown
-
2017
- 2017-05-24 US US15/604,523 patent/US20170258876A1/en not_active Abandoned
-
2018
- 2018-03-20 IL IL258237A patent/IL258237B/en active IP Right Grant
-
2022
- 2022-02-07 US US17/650,220 patent/US20220265783A1/en active Pending
Patent Citations (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5559212A (en) | 1988-04-06 | 1996-09-24 | Alfacell Corporation | Frog embryo and egg-derived tumor cell anti-proliferation protein |
US5728805A (en) | 1988-04-06 | 1998-03-17 | Alfacell Corp. | Pharmaceuticals and method for making them |
US6239257B1 (en) | 1998-12-30 | 2001-05-29 | Alfacell Corporation | Family of proteins belonging to the pancreatic ribonuclease a superfamily |
US6175003B1 (en) | 1999-09-10 | 2001-01-16 | Alfacell Corporation | Nucleic acids encoding ribonucleases and methods of making them |
US6423515B1 (en) | 1999-09-10 | 2002-07-23 | Alfacell Corporation | Methods of making nucleic acids encoding ribonucleases |
US7556953B2 (en) | 2003-07-17 | 2009-07-07 | Alfacell Corporation | Nucleic acid encoding a novel ribonuclease having an amino acid sequence made up of the amino acid sequence of a known ribonuclease and an N-terminal leader sequence |
US7763449B2 (en) | 2003-07-17 | 2010-07-27 | Alfacell Corporation | Nucleic acid encoding a novel ribonuclease having an amino acid sequence made up of the amino acid sequence of a known ribonuclease and an N-terminal leader sequence that is at least one residue long |
US7442535B2 (en) | 2003-07-17 | 2008-10-28 | Alfacell Corporation | Fusion protein incorporating a cysteinized ribonuclease |
US7473542B2 (en) | 2003-07-17 | 2009-01-06 | Alfacell Corporation | Cysteinized ribonuclease and targeting moiety conjugated thereto |
US7442536B2 (en) | 2003-07-17 | 2008-10-28 | Alfacell Corporation | Cysteinized ribonuclease and targeting moiety conjugated thereto |
US7229824B2 (en) | 2003-07-17 | 2007-06-12 | Alfacell Corporation | Ribonucleases and methods of making them recombinantly |
US7556952B2 (en) | 2003-07-17 | 2009-07-07 | Alfacell Corporation | Nucleic acid encoding a novel ribonuclease having an amino acid sequence made up of a known amino acid sequence and an initial N-terminal residue |
US7556951B2 (en) | 2003-07-17 | 2009-07-07 | Alfacell Corporation | Nucleic acid encoding a novel ribonuclease having an amino acid sequence made up of the amino acid sequence of a known ribonuclease and an n-terminal leader sequence that is at least one residue long |
US7585655B2 (en) | 2003-07-17 | 2009-09-08 | Alfacell Corporation | Nucleic acid encoding a fusion protein incorporating a cysteinized ribonuclease |
US7585654B2 (en) | 2003-07-17 | 2009-09-08 | Alfacell Corporation | Nucleic acid encoding cysteinized ribonuclease to which a targeting moiety can be conjugated |
US20090047665A1 (en) * | 2003-09-11 | 2009-02-19 | Ibis Biosciences, Inc. | Compositions for use in identification of adenoviruses |
US8518399B2 (en) | 2010-11-17 | 2013-08-27 | Tamir Biotechnology, Inc. | Methods of treating infections originating from viruses in the herpesviridae family |
US8808690B2 (en) | 2010-11-17 | 2014-08-19 | Tamir Biotechnology, Inc. | Methods of treating infections originating from viruses in the herpesviridae family |
US8663964B2 (en) | 2011-07-20 | 2014-03-04 | Tamir Biotechnology, Inc. | Methods of treating human papillomavirus |
WO2015110429A1 (en) * | 2014-01-22 | 2015-07-30 | Nicox S.A. | Composition effective against viral conjunctivitis |
WO2016205109A1 (en) | 2015-06-15 | 2016-12-22 | Tamir Biotechnology, Inc. | Pharmaceuticals for treatment of viral infections of the eye |
Non-Patent Citations (12)
Title |
---|
"Antiviral for Ocular Adenovirus Infections", INVEST. OPHTHALMOL. VIS. SCI., vol. 50, 2009, pages 5295 - 5299 |
"Goodman & Gilman's The Pharmacological Basis of Therapeutics", 2001, MCGRAW-HILL PROFESSIONAL |
"Handbook of Biodegradable Polymers", 1997, OVERSEAS PUBLISHERS ASSOCIATION |
"Handbook of Pharmaceutical Excipients", 2003, APHA PUBLICATIONS |
"Pharmaceutical Dosage Forms and Drug Delivery Systems", 1999, LIPPINCOTT WILLIAMS & WILKINS PUBLISHERS |
"REMINGTON: THE SCIENCE AND PRACTICE OF PHARMACY", 2000, LIPPINCOTT, WILLIAMS & WILKINS |
KAYCALANDRA: "Interpretation of Eye Irritation Tests", J. SOC. COS. CHEM., vol. 13, 1962, pages 281 - 289 |
REPETTO ET AL.: "Neutral Red Uptake Assay for the Estimation of Cell ViabilitylCytotoxicity", NAT. PROTOC., vol. 3, 2008, pages 1125 - 1131 |
ROMANOWSKI ET AL.: "The In Vitro and In Vivo Evaluation of ddC as a Topical Antiviral for Ocular Adenovirus Infections", INVEST. OPHTHALMOL. VIS. SCI., vol. 50, 2009, pages 5295 - 5299, XP055581166, DOI: 10.1167/iovs.08-3286 |
See also references of EP3353304A4 |
SUHASINI ET AL.: "Transfer RNA Cleavages by Onconase Reveal Unusual Cleavage Sites.", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 281, 5 May 2006 (2006-05-05), pages 12201 - 12209, XP055371838 * |
TORRENT ET AL.: "Bactericidal Activity Engineered on Human Pancreatic Ribonuclease and Onconase", MOL. PHARM., vol. 6, no. 2, 2009, pages 531 - 542 |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019222533A1 (en) * | 2018-05-18 | 2019-11-21 | Okogen, Inc. | Methods of treating ocular melanoma |
WO2021216909A1 (en) * | 2020-04-23 | 2021-10-28 | Okogen, Inc. | Treatment of viral conjunctivitis |
Also Published As
Publication number | Publication date |
---|---|
IL258237A (en) | 2018-05-31 |
JP6794454B2 (en) | 2020-12-02 |
US20170087223A1 (en) | 2017-03-30 |
US20220265783A1 (en) | 2022-08-25 |
SG10201912974VA (en) | 2020-03-30 |
IL258237B (en) | 2021-06-30 |
AU2016326750A1 (en) | 2018-04-19 |
CA2999514A1 (en) | 2017-03-30 |
MX2018003528A (en) | 2018-11-09 |
RU2733432C1 (en) | 2020-10-01 |
US20170258876A1 (en) | 2017-09-14 |
EP3353304B1 (en) | 2022-10-19 |
AU2016326750B2 (en) | 2022-09-15 |
JP2018535249A (en) | 2018-11-29 |
EP3353304A4 (en) | 2019-05-22 |
EP3353304A1 (en) | 2018-08-01 |
US9682130B2 (en) | 2017-06-20 |
CN108350458B (en) | 2022-06-07 |
KR20180058791A (en) | 2018-06-01 |
CN108350458A (en) | 2018-07-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20220265783A1 (en) | Viral conjunctivitis treatment using ranpirnase and/or amphinase | |
JP6307202B1 (en) | Novel iodophor composition and method of use | |
JP6862366B2 (en) | Drugs for the treatment of viral infections of the eye | |
US20200190158A1 (en) | Recombinant modified fibroblast growth factors and therapeutic uses thereof | |
US10357453B2 (en) | Methods of eye treatment using therapeutic compositions containing dipyridamole | |
US9011845B2 (en) | Methods for treatment of inflammatory and infectious viral diseases | |
JP2020531586A (en) | Methods and compositions for antiviral applications of synthetic lysine analogs and mimetics | |
US10603303B2 (en) | Transient receptor potential cation channel subfamily M member 8 (TRPM8) antagonists and methods of use | |
US20230218726A1 (en) | Treatment of viral conjunctivitis | |
JP7459298B2 (en) | A composition for preventing or treating macular degeneration containing a cell-permeable nucleic acid complex as an active ingredient | |
US20240035033A1 (en) | Prevention and treatment of age-related macular degeneration through suppression of cathepsin s expression | |
US20130344049A1 (en) | Methods for treatment of ocular diseases | |
TW202002980A (en) | Methods of use and pharmaceutical compositions of a selective SYK inhibitor | |
RU2068691C1 (en) | Agent for treatment of viral diseases caused by herpes virus | |
Chang | New drugs in the ophthalmic pipeline: ROCK inhibitors, SEGRA compounds and SIRT proteins might be unfamiliar to you now. But you may soon see them in topical drops | |
EA008737B1 (en) | Preparation for the treatment and prophylaxis of conjunctivitis and keratitis of different etiology (variants), method for use thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 16849832 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 258237 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 11201802287Q Country of ref document: SG |
|
ENP | Entry into the national phase |
Ref document number: 2999514 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/A/2018/003528 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2018536072 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2016326750 Country of ref document: AU Date of ref document: 20160925 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 20187011450 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2018109568 Country of ref document: RU Ref document number: 2016849832 Country of ref document: EP |